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Abstract: We describe here the design, multicomponent 
synthesis, biological studies, molecular modeling, ADMET, and 
in vitro PAMPA-BBB analysis of new tacrine-ferulic acid hybrids 
(TFAHs). We have identified TFAH 10n as interesting 
multipotent compound showing moderate, and totally selective, 
hBuChE inhibition (IC50=68.2 nᴍ), strong antioxidant activity 
(4.29 μmol of trolox equivalents, ORAC), and anti-aggregating 
properties (65.6% at 1:1 ratio), being able to penetrate CNS 
(PAMPA-BBB assay). Noteworthy, even when tested at a very 
high concentration TFAH 10n surpasses by far the other TFAHs 
in the hepatotoxicity profile (59.4% cell viability at 1000 µᴍ), 
affording good neuroprotection capacity against toxic insults 
such as A1-40, A1-42, H2O2, and oligomycin A/rotenone on SH-
SY5Y cells, at 1 µᴍ. The results reported here support and 
strengthen the interest on the development of new multipotent 
TFAHs derivatives as potential drugs for AD patients cure. 
 
Introduction 
Alzheimer’s disease (AD) is a neurodegenerative disorder 
characterized by progressive cognitive impairment and memory 
loss, associated with the deficit in the cholinergic 
neurotransmission.[1] Histological changes underlying this 
disorder are amyloid plaques of -amyloid (A) peptide, 
neurofibrillary tangles (NFT), a dramatic loss of synapses and 
neurons, and a decreased level of choline acetyltransferase that 
correlates with a decline in the mental status scores.[2]  
Due to the multi-pathogenesis of AD, one of the current 
drug discovery approaches for AD treatment focuses on 
compounds with a multitarget biological profile, the so called 
Multi-Target Directed Ligands (MTDLs).[3] The so far developed 
MTDLs include derivatives which can simultaneously restore the 
brain acetylcholine (ACh) levels, reduce the oxidative stress, 
inhibit A aggregation, and protect neuronal cells against toxic 
insults.[4–6] Two cholinesterase enzymes, acetylcholinesterase 
(AChE) and butyrylcholinesterase (BuChE), are responsible for 
the hydrolysis of the neurotransmitter ACh in the brain. Recent 
evidence has highlighted non classic role for cholinergic 
enzymes which may be important in the light of developing more 
effective drugs for AD. Indeed, it was shown that several AChE 
inhibitors (AChEIs) not only facilitate cholinergic transmission, 
but also interfere with the synthesis, deposition and aggregation 
of toxic A.[7,8] On the other hand, other studies suggested that 
BuChE may also influence the aggregation of A into neuritic 
plaques and formation of the NFT deposit.[9,10] Oxidative stress is 
also thought to play a key role in the pathogenesis of AD. Indeed, 
many studies showed that senile plaques release reactive 
oxygen species (ROS),[11] whose accumulation damages major 
cell components, such as the nucleus, mitochondrial DNA, 
membranes, and cytoplasmic proteins.[12]   
Notwithstanding the impressive progress in the 
understanding of the molecular mechanisms at the basis of AD, 
nowadays an effective drug is still not available and AChEIs, 
such as rivastigmine, galantamine and donepezil, remain the 
principal class of available drugs for the treatment of this 
disease.[13] Tacrine 1 (Figure 1) a potent, submicromolar human 
AChEI, the first approved drug[14] by FDA for the treatment of AD in 
1993, was withdrawn shortly after its approval,
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toxicity. In spite of this, studies on tacrine analogues have been 
continued
[16]
 in the search of more potent and safer tacrine 
derivatives. In this light, it is worth to mention that the 7-methoxy 
derivative of tacrine (7-MEOTA, 9-amino-7-methoxy-1,2,3,4-
tetrahydroacridine)
[17]
 (2, Figure 1), showed reduced hepatotoxicity 
when compared to tacrine.
[18–20]
 
 
Figure 1. Structures of tacrine (1), 7-MEOTA (2) and tacrine-ferulic acid 
hybrids 3 and 4. 
On the other hand, based on the MTDLs approach, recent 
reports have described tacrine hybrids, prepared by connecting 
tacrine, or its derivatives to other pharmacologically relevant 
scaffolds with the aim to overcome tacrine’s hepatotoxicity[21] 
among them which the tacrine hybrids, such as the antioxidant 
tacrine-ferulic acid-nitric oxide (NO) donor (hybrid 3, Figure 1),[22] 
or the tacrine-caffeic acid (hybrid 4, Figure 1).[23] One of us has 
recently shown that tacrine-ferulic acid hybrid (TFAH 5a, Figure 
2) is a moderate antioxidant and potent reversible, non-
competitive AChEI. Hybrid 5a is able to bind the peripheral 
binding site (PAS) of the AChE, showing almost equipotent 
capacity to inhibit EeAChE and eqBuChE.[24] In addition the 
TFAH 5b (Figure 2) described by Pi et al.[25] showed significant 
in vitro inhibition of AChE-induced and self-induced A1–40 
aggregation and blocked the cell death induced by A1–40 in 
PC12 cells.  
From a synthetic point of view, multicomponent reactions 
have emerged as the method of choice for introducing molecular 
diversity.[26] Therefore, they seem well-suited for the search of 
new molecules having different moieties of interest and able to 
interact with various physiopathological events in connexion with 
AD.[4,27–29] Particularly interesting among these types of reactions 
is the Ugi four-component reaction. This transformation allows 
creating up to five points of structural diversity in one-pot which 
can be very useful for the expeditious synthesis of bioactive 
molecules for multifactorial diseases such as AD.[30] 
In this context and following a docking-driven combinatorial 
strategy, Dickerson et al. have prepared a library of Ugi adducts 
based on a planar and rigid naphthalene moiety, the so-called 
“credit-card” compounds.[31] As an example, the adduct 5c 
depicted in Figure 2, is only able to fix to the hydrophobic PAS of 
AChE, with its naphthalene moiety, which disrupts the existing 
hydrophobic interactions between AChE and A, therefore 
inhibiting AChE-induced A aggregation. Furthermore, authors 
have also reported that the observed inhibitory activity is not 
simply elicited by the naphthalene fragment but very likely also 
due to the presence of the substituted -acylaminocarboxamide 
backbone.  
Considering these precedents and in order to take 
advantage of the chemical diversity rapidly achievable by the 
Ugi reaction as a part of the discovery of new MTDLs for AD 
therapy, we report here the design, synthesis and biological 
evaluation of a new family of TFAHs, namely (E)-3-(4-hydroxy-3-
methoxyphenyl)-N-alkyl-N-[2-oxo-2(amino)ethyl]acrylamides (I, 
Figure 2). These molecules possess a substituted glycine 
substructure being part of the main -acylaminocarboxamide 
backbone. Consequently, the new adducts contains a tacrine or 
a 7-MEOTA motifs, and a feruloyl group, both tethered to the 
glycine fragment. The carbonyl group of the glycine part has 
been functionalized as an amide either by benzylamine, 2’-
chloro-6’-methylaniline or 2’-naphthylamine which should confer 
potential and additional anti-cholesterasic, and antioxidant 
properties to the target molecules. In addition, we have 
hypothesized that the substituted glycine substructure in our 
adducts would afford additional aromatic groups able to bind at 
the AChE’s hydrophobic PAS, with potential consequences on 
the aggregation of A.[32] 
Therefore, we have synthesized fourteen new TFAHs, 
identified as hybrids 10a-n (Figure 3), and evaluated their 
hepatotoxicity on HepG2 cells, the neuroprotective capacity of 
some selected hybrids against several toxic insults such as A1-
40, A1-42, H2O2, and oligomycin A/rotenone, as well as their ChEs 
inhibition, A1-42 self-aggregation inhibition, antioxidant activity 
(ORAC-FL scavenging test).  
From these studies, we have identified TFAH 10n [(E)-3-
(4-hydroxy-3-methoxyphenyl)-N-(8-((7-methoxy-1,2,3,4-
tetrahydroacridin-9-yl)amino)octyl)-N-(2-(naphthalen-2-ylamino)-
2-oxoethyl)acrylamide], as new and very promising multipotent 
hit molecule for further drug discovery steps for AD. 
Published in ChemMedChem 2015, 10, 523-539 (http://dx.doi.org/10.1002/cmdc.201402409) 
 
 
 
 
 
Figure 2. Structures of compounds 5a-c, and the general structure for the new  
(E)-3-hydroxy-3-methoxyphenyl-N-alkyl-N-[(2-oxo-2-amino)ethyl]acrylamides I 
described in this work. 
Results and Discussion 
Chemistry 
 
The synthesis of the target TFAHs 10a-n has been carried out 
using the short synthetic procedure depicted in scheme 1, with 
good overall yields.  
9-chlorotacrines 8a-b were synthesized following known 
procedures.[33–35] The latter chloro compounds were then reacted 
with the suitable alkylenediamines in refluxing 1-pentanol to 
obtain the diamines 9a-f. Diamines were then reacted, by the 
one-pot U-4CR, with formaldehyde, ferulic acid and selected, 
commercial isocyanides, in MeOH/CH2Cl2 (3:1, v/v) at room 
temperature for 24 h,  to obtain the expected TFAHs 10a-n in 
16%-48% yield range (Scheme 1).[36]  
All new TFAHs showed analytical and spectroscopic data 
in good agreement with their structure. The structural 
characterization of the synthesized (E)-3-(4-hydroxy-3-
methoxyphenyl)-N-alkyl-N-[2-oxo-2-(amino)ethyl]acrylamides 
10a-n was carried out by NMR. At 298 K, these compounds 
showed broadened NMR spectra or even multiple NMR signals 
indicative of their conformational mobility, which is related to the 
existence of two or more conformers in solution, as confirmed by 
an in-depth NMR analysis on selected compounds (variable 
temperature 1H, 13C, gCOSY, TOCSY, NOESY, ROESY, 
multiplicity-edited gHSQC and 
gHMBC) (see Supporting 
Information).  
Hybrids 10a-k bear a tacrine 
moiety while TFAHs 10l-n are 
7-MEOTA derivatives. As 
shown in scheme 1, in the 
tacrine hybrids 10a-k, R2 may 
be either benzyl, 2’-chloro-6’-
methylphenyl, or 2’-naphthyl 
group, depending of the 
commercial isocyanide used for 
their synthesis, and the length 
of the linker varies between 5 
and 9 methylene units. On the 
other hand, for hybrids 10l-n, 
the linker was kept at n= 8, 
while, similarly to hybrids 10a-k, 
R2 may be a benzyl, 2’-chloro-
6’-methylphenyl, or 2’-naphthyl 
residue. 
 
Biological evaluation 
 
The in vitro biological evaluation 
of the new TFAHs 10a-n started 
with the investigation of the 
toxicity profile on HepG2 cells, 
and continued with the determination of the ability of the new 
TFAHs to possess a suitable activity profile on the selected 
targets, including neuroprotection, inhibition of ChEs activity, 
antioxidant capacity and inhibition of the Aβ1-42 self-aggregation. 
 
Evaluation of hepatoxicity on HepG2 cells  
For the tacrine hybrids 10a-n, the first and the most critical 
aspect was the evaluation of the hepatotoxicity[37] (see 
Experimental Part), in a wide concentration range (1-1000 µᴍ). 
The assay was carried out on HepG2 cells using the MTT assay 
for the cell viability test.[38] As expected, tacrine showed a dose-
dependent cell toxicity (Table 1), the inflexion point starting at 
100 µᴍ. In general, the hepatotoxic effect of TFAHs 10a-n after 
24 h incubation was lower than that exerted by tacrine. 
Concerning the structure-activity relationships (SAR), and based 
on the observed values at 1000 µᴍ (the highest concentration 
investigated), several conclusions can be drawn. Not 
surprisingly, and in agreement with the rationale of their design, 
the hybrids carrying the 7-MEOTA fragment (10l-n) were less 
toxic than the tacrine hybrids. Only TFAHs 10a and 10h showed 
similar cell toxicity. The less toxic derivatives at 1000 µᴍ were 
10n and 10m, bearing both an octamethylene linker, and a 2’-
naphthyl or a benzyl group, respectively, (1.72-fold less toxic 
than tacrine). The most toxic was compound 10i bearing a 2’-
naphthyl group as R2, and a hexamethylene linker. Among 
tacrine hybrids 10a-e, bearing a 2’-chloro-6’-methylphenyl group, 
the less toxic compound 10a (1.47-fold less toxic than tacrine at 
1000 µᴍ) has a pentamethylene linker, but toxicity increased 
going to TFAH with n= 6 and n= 7, and decreased in compound 
10e with a nonamethylene linker. A similar trend was also 
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observed in TFAHs 10f-h bearing a benzyl as R2 with the less 
toxic 10h (1.64-fold than tacrine), and in 10i-k a 2’-naphthyl as 
R2, the longer linker, the lesser toxic remained.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1. Synthesis of TFAHs 10a-n. Reagents, conditions and range yields. 
(a) NH2(CH2)nNH2 (3.0 equiv), 1-pentanol, reflux, 18 h (54-66%); (b) 
Formaldehyde, ferulic acid, isocyanides (benzylisocyanide, 2-chloro-6-
methylphenyl isocyanide, 2-naphthyl isocyanide), MeOH/CH2Cl2 (3:1, v/v), rt, 
24 h (16-48%). 
 
As final consideration, the type of substituent at the glycine 
fragment seems to influence the extent of the toxicity on HepG2 
cells. Indeed, very interestingly, comparing the toxicity of hybrids 
with the same length of the linker, and different R2, the 
compounds bearing the benzyl group [10f (n= 6), 10g (n= 7), 
10h (n= 8)] were always less toxic than their analogues bearing 
2’-naphtyl and 2’-chloro-6’-methylphenyl group. 
Neuroprotective capacity of TFAHs 10a-n  
The neuroprotective capacity of the five least hepatotoxic 
compounds 10a, 10e, 10h, 10m and 10n were tested for their 
ability to prevent the human neuroblastoma cell line SH-SY5Y 
from cell death induced by three toxicity models : (i) Apeptides 
(A1-40 and A1-42) which are implicated in apoptosis-related 
signaling pathways and ROS production,[39] (ii) hydrogen 
peroxide (H2O2) for the generation of exogenous free radicals 
and (iii) the mixture of oligomycin A plus rotenone (O/R), two 
mitochondrial respiratory chain blockers, which produce 
mitochondrial ROS by respectively inhibiting complex V and I of 
the mitochondrial electron transport chain. Thus, compounds 
able to halt or hamper these toxic insults may be considered as 
neuroprotectants.[40] However, prior to the evaluation of the 
neuroprotective capacity, direct cell toxicity of the selected 
TFAHs was investigated at 1, 3 and 10 µᴍ. In these experiments, 
cell viability was measured by using the MTT assay.[38] As 
shown in table 2, TFAH 10a and 10n are not toxic at all tested 
concentrations, whereas 10e, 10h, 10m show significant and 
high toxicity at 3 and 10 µᴍ, respectively. At 1 µᴍ, 10h and 10m 
remains not toxic at 1 µᴍ, but show significant and high toxicity 
at 3 and 10 µᴍ, respectively. Consequently, cell assays on 
neuroprotection were carried out at 0.3 and 1 µᴍ for 10a, 10e 
and 10h, at 1 µᴍ for 10m and at 1 and 3 µᴍ for 10n. TFAH 10m 
showed poor neuroprotection against H2O2 and O/R, but 
displayed a very high and significant neuroprotection against the 
A1-42 insult and a moderate effect against A1-40 (Table 3). 
Interestingly, at the same concentration, 10n showed an 
opposite, but quantitatively similar, behavior on A-related cell 
toxicity, showing in addition a moderately significant 
neuroprotection against H2O2 and O/R. However, at 3 µᴍ, the 
neuroprotection given by compound 10n against H2O2 and O/R 
is drastically reduced, while concerning A-induced cell toxicity, 
a reversed trend is observed, being a more effective but still 
moderate, neuroprotective agent against cell toxicity induced by 
A1-42. Very interesting, the overall results obtained for TFAHs 
10a, 10e and 10h are better than 10n at 1 µᴍ. Indeed, those 
compounds display almost the same moderate neuroprotection 
against O/R and significant to higher neuroprotection against 
H2O2 and cell toxicity induced by A1-42. On the other hand at 0.3 
µᴍ the neuroprotective effect is reduced against A1-42 but is 
increased for 10e and 10h against O/R.  
 
Inhibition of EeAChE/eqBuChE 
In the first exploratory experiments, we used the cheap and 
easily available EeAChE and eqBuChE, using tacrine as 
reference, and the Ellman protocol for the determination of the 
inhibitory potency.[41]  
As shown in table 4, the less hepatotoxic 7-MEOTA derivatives 
10l-n, showing also interesting neuroprotective properties, were 
the least potent ChEIs among all the TFAHs investigated here. 
Conversely, the TFAHs 10a-k were potent BuChEI, with IC50 
values in the nanomolar range, showing selectivities from 115.5 
(TFAH 10a) to 1.6 (TFAH 10b). The most potent eqBuChEI 
being TFAH 10a (IC50=1.0±0.2 nᴍ, 5.1-fold more potent than 
tacrine) and the most potent EeAChEI being compound 10c 
(IC50=6.2±0.7 nᴍ, 7.2-fold more potent than tacrine). 
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Regardless the influence of the linker, TFAHs 10a-e bearing the 
2’-chloro-6’-methylphenyl group were more potent eqBuChEI 
than those bearing the benzyl (10f-h) or the 2’-naphthyl (10i-k) 
groups. Regarding the influence of 
the length of the linker on the 
activity, in the 10a-e hybrids, the 
best eqBuChE inhibitory activity was 
found for n=5, progressively 
decreasing from n=6 to n=9, but 
remains quite stable around an IC50 
values of 2.61 nᴍ. However, for 
compounds 10f-h, the activity 
progressively increased from n= 6 
to n= 8, and in the 10i-k series the 
order of activity, from the most to 
less potent, was 8>6>7. Regarding 
equipotency for EeAChE and 
eqBuChE, TFAH 10c and 10d were 
found the most balanced, showing 
IC50 values around 6.3 nᴍ and 2.5 
nᴍ, respectively. Overall, 
considering the toxicity, and ChEI 
data, we have concluded that the 
most balanced compounds are 10h, 
10a and 10e, in this order, as they 
are 1.5-, 1.45- and 1.34-fold less 
toxic than tacrine at 300 µᴍ, with 
high eqBuChEI activity, and from 
potent to moderate EeAChE 
inhibitory activities. Based on these 
results, it was quite satisfactory to 
find that our initial hopes regarding 
the use of a tacrine-grafted -
acylaminocarboxamide backbone in 
the new TFAHs 10a-k, were fullfiled 
in terms of synthetic access and 
ChEs inhibition profiles. Thus, these 
results allowed us to go further and to analyze the capacity of 
TFAHs to inhibit human ChEs. 
 
Inhibition of human AChE/human BuChE and kinetic 
inhibition studies 
As shown in table 4, and in agreement with data obtained on 
EeAChE, the less toxic 7-MEOTA derivatives 10l-n were the 
less potent hChEIs but better than 7-MEOTA itself (2, Figure 1). 
TFAHs 10a-k were potent hAChE inhibitors with IC50 values in 
the nanomolar range and very potent hBuChE inhibitors, with 
selectivities ranging from 292.3 (hybrid 10k) to 40.9 (hybrid 10h). 
The IC50 values for the inhibition of hBuChE were much lower for 
the same compound for any of the 10a-e (from 0.307 to 0.968 
nᴍ), 10f-h (from 0.98 to 2.51 nᴍ), 10i-k (from 0.260 to 2.48 nᴍ) 
series compared to the eqBuChE inhibition data. The most 
potent hBuChEI was TFAH 10k (IC50=0.260±0.021 nᴍ, 176.1-
fold more potent than tacrine). For the same length in the linker, 
TFAHs 10a-e, bearing the 2’-chloro-6’-methylphenyl group, were 
more potent hBuChEI than those bearing the benzyl (10f-h) or 
the 2’-naphthyl (10i-j) groups, except 10k. Regarding the 
influence of the linker on the activity, 
Table 1. In vitro toxicity of tacrine and TFAHs 10a-n in HepG2 cells.
[a]
 
Compd 1 µᴍ 3 µᴍ 10 µᴍ 30 µᴍ 100 µᴍ 300 µᴍ 1000 µᴍ 
10a 99.31.7
ns
 98.91.7
ns
 96.41.3
ns
 66.11.1***
 
62.91.3*** 57.92.5*** 50.94.1*** 
10b 99.51.3
ns
 87.41.2** 85.91.6*** 71.41.1*** 48.72.0*** 47.52.0*** 43.21.1*** 
10c 96.11.1
ns
 88.81.3
ns
 85.41.8* 82.41.5** 50.52.6*** 46.84.1*** 43.53.1*** 
10d 98.40.7
ns
 96.31.4
ns
 88.71.1* 83.81.4*** 50.22.6*** 50.62.2*** 43.31.9*** 
10e 100.01.4
ns
 97.61.6
ns
 95.60.3
ns
 71.81.7*** 54.21.1*** 53.50.7*** 47.22.9*** 
10f 97.01.9
ns
 92.32.1
ns
 91.81.9
ns
 92.71.9
ns
 63.33.7*** 50.53.8*** 48.94.4*** 
10g 85.32.4
ns
 79.03.8* 76.01.3** 73.13.9** 47.23.1*** 47.03.4*** 46.32.1*** 
10h 95.21.5
ns
 95.21.7
ns
 94.41.7
ns
 81.21.0*** 61.80.2*** 60.11.0*** 56.32.0*** 
10i 97.12.6
ns
 96.00.4
ns
 94.81.6
ns
 89.71.9
ns
 48.02.8*** 40.72.3*** 36.31.9*** 
10j 99.21.4
ns
 95.00.8
ns
 94.50.3
ns
 92.81.2
ns
 63.22.9*** 44.21.3*** 39.32.0*** 
10k 97.50.3
ns
 96.10.6
ns
 95.91.4
ns
 91.80.9
ns
 74.62.8*** 46.81.4*** 46.12.3*** 
10l 93.52.4
ns
 94.51.5
ns
 88.81.6*** 56.60.9*** 51.41.7*** 52.41.4*** 50.81.0*** 
10m 100.31.1
ns
 98.91.8
ns
 97.92.8
ns
 98.10.9
ns
 97.02.7
ns
 60.32.9*** 59.21.6*** 
10n 98.82.4
ns
 97.01.8
ns
 92.03.0
ns
 94.03.8
ns
 83.22.5* 74.01.4*** 59.44.7*** 
Tacrine 93.44.7
ns
 903.0
ns
 88.73.4
ns
 81.64.9* 64.34.5*** 402.2*** 34.42.7*** 
 
[a] The cell viability was measured as MTT reduction and data were normalized as % of control. Data are 
expressed as the means ± SEM of triplicate of at least three different cultures. All compounds were assayed at 
increasing concentrations (1-1000 µᴍ). ***P< 0.001, **P< 0.01, *P<0.05 and ns:
 
not significant, with respect to 
control group. Comparison between tested hybrids and control group was performed by one-way ANOVA 
followed by the Newman–Keuls post-hoc test.  
 
 
 
Table 2. SH-SY5Y cell viability in the presence of  TFAHs 10a, 10e, 10h, 
10m and 10n.
[a]
 
Compd 1 µᴍ 3 µᴍ 10 µᴍ 
10a 99.9±6.7
ns 
100.2±5.5
ns
 90.8±1.6
ns
 
10e 94.6±5.2
ns
 85.5±5.8
ns
 10.0±3.5*** 
10h 91.7±0.6
ns
 81.6±4.3* 9.9±2.6*** 
10m 99.7±1.4
ns 
79.4±4.7** 40.1±1.9*** 
10n 98.9±0.9
ns 
97.5±1.2
ns 
95.1±1.4
ns 
[a] All compounds were assayed for 24 h. ***P≤0.001, **P≤0.01. ns: not 
significant with respect to basal. Data are expressed as the means ± SEM 
of triplicate of at least five different cultures. 
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in TFAHs 10f-h and TFAHs 
10i-k hybrids, the hBuChE 
inhibition was decreasing going  
from n=6 to n=8. For the 
TFAHs 10a-e, the best was 
found for n=7 but remaining 
quite stable in the IC50 values,  
around 0.32 nᴍ, on going from 
n=7 to n=9. Concerning 
inhibition of hAChE, the most 
potent was compound 10e 
(IC50=14.3±1.1 nᴍ, 29.6-fold 
more potent than tacrine). The 
influence of the linker on 
activity was observed: the IC50 
value decreased when going 
from n=6 to n=9 for TFAHs 
10b-e and from n=6 to n=8 for 
TFAHs 10f-h and 10i-k. 
Regarding equipotency for 
hAChE and hBuChE, TFAH 
10e was found to be the most 
balanced, showing IC50 values 
equal to 14.3 nᴍ and 0.318 nᴍ, 
respectively for hAChE and 
hBuChE. However, TFAH 10h 
is the most balanced of the 
multipotent hybrids, less toxic 
than tacrine, able to strongly 
inhibit human AChE and 
BuChE.  
As general consideration, 
the mechanism of hAChE 
inhibition of TFAH 10h has 
been therefore investigated by 
building Lineweaver-Burk 
double reciprocal plots. 
Lineweaver-Burk plots showed 
increasing slopes and 
increasing intercepts with 
higher inhibitor concentration. 
The interception of the lines 
above the x-axis (Figure 3) 
indicates that hybrid 10h is 
able to interact with both the 
free and acylated enzyme and 
behaves as mixed-type 
inhibitor of hAChE. The 
inhibitor dissociation constants 
Ki (dissociation constant for the 
enzyme-inhibitor complex) and 
K’i (dissociation constant for 
the enzyme-inhibitor-substrate 
complex) were estimated and 
resulted to be 44.1 and 57.2 
nᴍ, respectively. Encouraged 
by these results and in order to 
investigate the multipotency of 
Table 3. Protective effect of TFAHs 10a,10e, 10h, 10m and 10n on SH-5YSY cell death induced by A1-40 (30 µᴍ), A1-
42 (30 µᴍ), H2O2 (300 µᴍ), or Oligomycin A (10 µᴍ)/Rotenone (30 µᴍ).
[a]
 
Compd (conc.) A1-40 A1-42 H2O2 O/R 
10a (0.3 µᴍ) n.d. 24.7±3.6* n.d. 22.3±2.9** 
10a (1 µᴍ) n.d. 52.3±4.2*** 76.6±1.5*** 30.5±1.6** 
10e (0.3 µᴍ) n.d. 38.1±2.0** n.d. 39.9±1.4*** 
10e (1 µᴍ) n.d. 57.2±3.9*** 57.4±2.8*** 30.1±0.7** 
10h (0.3 µᴍ) n.d. 16.4±1.7* n.d. 37.3±2.0*** 
10h (1 µᴍ) n.d. 65.4±3.8*** 56.8±3.3*** 30.6±0.6** 
10m (1 µᴍ) 42.0±1.4* 80.2±4.2*** 2.3±3.8
ns
 15.2±2.3
ns
 
10n (1 µᴍ) 74.7±1.2*** 46.3±4.9* 52.7±6.2* 40.0±2.0* 
10n (3 µᴍ) 49.8±2.4** 59.7±4.2** 19.9±3.6
ns
 21.9±1.6
ns
 
 
[a] Data are expressed as % neuroprotection ± SEM of triplicate of at least four different cultures. ***P0.001, **P0.01, 
*P0.05, ns: not significant, with respect to control. O/R stands for Oligomycin A/Rotenone, n.d.: not determined. 
 
Table 4. Inhibitions (IC50, nᴍ) of EeAChE, eqBuChE, hAChE, hBuChE by TFAHs 10a-n and reference compounds. 
Compd n EeAChE
[a]
 eqBuChE
[a]
 Selectivity
[b] 
hAChE
[d]
 hBuChE
[d]
 Selectivity
[e] 
10a 5 115.5±6.5 1.0±0.2 115.5 52.3±4.3 0.717±0.038 72.9 
10b 6 5.4±0.6 3.3±0.3 1.6 102±6 0.968±0.055 105.4 
10c 7 6.2±0.7 2.6±0.3 2.4 70.0±4.1 0.307±0.020 228 
10d 8 6.5±0.1 2.4±0.1 2.7 42.5±2.9 0.336±0.028 126.5 
10e 9 26.8±1.9 3.0±0.3 9.0 14.3±1.1 0.318±0.024 45.0 
10f 6 14.6±2.1 6.0±1.9 2.4 169±10 2.51±0.17 67.3 
10g 7 14.1±0.9 2.8±0.1 5.0 71.0±4.3 1.06±0.07 67.0 
10h 8 7.6±0.4 2.8±0.1 2.7 40.1±2.8 0.98±0.09 40.9 
10i 6 48.4±0.4 9.1±1.3 5.3 174±15 2.48±0.21 70.2 
10j 7 25.3±4.8 11.7±2.2 2.2 65.0±3.3 0.737±0.071 88.2 
10k 8 14.9±1 5.9±0.3 2.5 76.5±6.8 0.260±0.021 294.2 
10l 8 134.3±8.1 88.9±5.7 1.5 2119±136 14.8±1.1 143.2 
10m 8 110.0±8.4 48.8±2.3 2.3 1326±43 49.0±2.6 27.1 
10n 8 51.9±3.5
[c]
 70.5±1.8
[c]
 - 22.2±1.6
[c]
 68.2±3.9 - 
7-MEOTA
 
- n.d. n.d.          - 13500±900 6400±420 2.1 
Tacrine - 44.3±1.5 5.1±0.2 8.7 424±21 45.83.0 9.3 
FA - n.d. n.d. - n.a. n.a. - 
 
[a] Inhibition curves were obtained by nonlinear regression. Ee: electric eel, eq: equine. Each IC50 value is the mean 
± SEM of quadruplicate of at least three different experiments. [b] Ratio IC50(EeAChE)/IC50(eqBuChE). [c] Inhibition 
percentage at 3 µᴍ. [d]
 
human recombinant AChE and human serum BuChE were used. Each IC50 value is the 
mean ± SEM of at least three different experiments. [e]
 
Ratio IC50(hAChE)/IC50(hBuChE). n.d. stands for not 
determined. n.a.=not active at the highest tested concentration (0.2 mᴍ). 
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the new TFAHs, the antioxidant activity and the ability to inhibit 
A1-42 self-aggregation were evaluated. 
 
 
 
Figure 3. Steady-state inhibition of hAChE hydrolysis of 
acetylthiocholine (ATCh) by TFAH 10h. Lineweaver-Burk 
reciprocal plots of initial velocity and substrate concentrations 
(0.11-0.56 ᴍ) are presented. Lines were derived from a 
weighted leastsquares analysis of data. 
 
Antioxidant activity  
The ability of hybrids 10a-n to reduce the amount of peroxyl 
radicals was determined by the ORAC-FL (Oxygen Radical 
Absorbance Capacity by Fluorescence) method,[42,43] using 
fluorescein (FL) as the fluorescent probe, and Trolox (6-hydroxy-
2,5,7,8-tetramethyl-chroman-2-carboxylic 
acid), as standard compound. Results were expressed as Trolox 
equivalents (µmol of trolox/µmol of tested compound). Ferulic 
acid was also tested, giving an ORAC value of 3.7, that fully 
agreed with the value previously described.[24] As shown in table 
5, all TFAHs derivatives presented a good ability to reduce a 
peroxyl radical and the ORAC values ranged between 3.43 
(TFAH 10i) and 7.74 (TFAH 10b) similarly to ferulic acid (3.7). 
TFAHs 10i-k, bearing the 2’-naphthyl group were the less potent 
with nearly the same value. Concerning the 7-MEOTA 
derivatives (10l-n) with the same length of the linker, the 
compound 10m, bearing a benzyl group, showed a higher 
activity than TFAH 10l and 10n. 
 
Inhibition of A1-42 self-aggregation  
The inhibitory activity of hybrids 10a-n against the spontaneous 
aggregation of Aβ1-42 was determined in vitro using a thioflavin T 
(ThT)-based fluorometric assay.[44] All TFAHs showed 
interestingly A1-42 antiaggregating activity (Table 5), displaying 
percentages of inhibition in the range 50.1−80.8% when tested 
at equimolar concentration with A1-42 ([Inhibitor]=[A1-42]=50 μᴍ). 
These data further confirm that these compounds are able to 
directly inhibit the formation of A toxic species, as already 
observed in cell based-assay (Table 3). Noteworthy, the 
reference compounds tacrine and 7-MEOTA were not able to 
significantly interfere with amyloid aggregation. The most potent 
A1-42 antiaggregating agent was TFAH 10e (80.8%), but the 7-
MEOTA derivatives 10l and 10m also showed excellent values 
around 72%, but no clear SAR could be drawn. 
 
Molecular modeling 
TFAH 10b (see Supporting Information), TFAH 10e (the most 
active compound against hAChE and the most potent A1-42 
antiaggregating agent) and TFAH 10h, the most active of the 
10f-h series, being the most balanced multipotent antioxidant 
hybrid, less toxic than tacrine, able to strongly inhibit hAChE and 
hBuChE, were used for docking with hAChE (PDB ID: 4EY7)[45] 
and hBuChE (PDB ID: 4BDS).[46] To note, flexibility and size of 
these ligands provided several solutions, though a deep 
Table 5. ORAC values and inhibition of self-induced A1-42 aggregation (% 
inhibition) by TFAHs 10a-n and reference compounds. 
Compd ORAC
[a] 
A1-42 self-aggregation
[b]
 
10a 6.89±0.08 73.5±0.2 
10b 7.74±0.26 50.1±2.8 
10c 6.40±0.47 75.0±1.1 
10d 5.29±0.16 76.7±0.8 
10e 4.41±0.04 80.8±1.5 
10f 5.75±0.32 67.9±4.2 
10g 7.04±0.24 75.0±1.2 
10h 6.40±0.47 69.3±3.5 
10i 3.43±0.16 72.0±0.3 
10j 3.57±0.11 69.0±1.5 
10k 3.44±0.09 73.0±1.5 
10l 4.79±0.39 72.4±1.3 
10m 6.47±0.10 72.1±3.2 
10n 4.29±0.19 65.6±0.9 
7-MEOTA n.d. <5% 
Tacrine 0.2±0.1
[24] 
<5% 
FA 3.7±0.1 n.d. 
[a] Data are expressed as μmol of trolox equivalents/μmol of tested 
compound and are shown as means ± SD. n.d.: not determined.  
[a] [A1-42]=50 µᴍ, [inhibitor]=50 µᴍ. 
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inspection of the binding modes and energy values led to the 
following putative binding modes.  
The modelling results suggest that TFAHs 10e and 10h 
are gorged into the catalytic amino acid triad (Ser203, His447 
and Glu334) of hAChE oriented along the active-site gorge, 
extending from the catalytic site at the bottom of the gorge, to 
the PAS near the mouth of the gorge, via hydrophobic 
interactions with various aromatic acid residues (Figure 4). 
Specifically, the predicted binding mode indicates that the 
tricyclic tetrahydroacridine moiety is engaged in the formation of 
 
Figure 4. Representation of the binding mode of compound 
TFAH 10e, as cyan stick, with hAChE (PDB id: 4EY7). The key 
residues that interact with the molecule are depicted as thin 
sticks in green. 
 
a characteristic cation–π interaction with Trp86 (the choline-
binding site) and T-shaped stacking interactions with Tyr337. 
The protonated form of tacrine unit gives hydrogen bond with the 
carbonyl group of His440. Steric clashes with the methoxy 
substituent at the tacrine unit in compounds 10l-n with the 
hydrophobic pocket formed by Tyr341 and Tyr337 could explain 
the decrease of the inhibitory activity.[47] At the mouth of the 
gorge, the ring of the 2’-chloro-6’-methylphenyl group (or the 
benzyl group in TFAH 10h) is π–stacked with Tyr72, a key 
residue in PAS. The presence of the electron- withdrawing 
chloro-substituent (TFAH 10e) on the aromatic pendant could 
lead to reinforcing π-π interaction, which also seems more 
effective due to a shorter R2 substituent (than those bearing the 
benzyl moiety as in TFAH 10h). 
In addition, the feruloyl moiety of the -acylaminocarboxamide 
backbone is H-bonded with Ser293 and interacts at PAS with 
the aromatic core of Trp286 in this predictive binding. It has 
been estimated that the PAS site was about 20 Å away from the 
CAS.[48] The extended conformation of TFAH 10e and TFAH 10h 
has a length of 21.2 and 20.8 Å from the tacrine unit wing to the 
end of the ferulic acid moiety, respectively, which was enough to 
cover both the PAS and CAS, leading our compounds acting as 
dual binding site inhibitors. Finally, the linker fills a hydrophobic 
pocket delineated by phenyl rings of Tyr121, Phe297, Tyr341, 
while the amine group is engaged in polar contacts with Gly120 
and Gly121. 
The inhibitor TFAH 10e was additionally docked with a 
method previously reported by Darras et al.[49] which takes seven 
structural water molecules of AChE into account (Figure 5). 
Thereby, the consistency of the binding mode throughout 
different docking programs should be explored. This leads to the 
finding of a theoretical binding mode which can explain 
interaction with CAS and PAS, too. The presented pose of TFAH 
10e shows the tacrine moiety located in the CAS. The tacrine 
can be stabilized by a 2.8 Å long hydrogen bond to Ser203. The 
alkyl linker spans the binding gorge and the amide residues, 
including the feruloyl, are located at the PAS of AChE (Figure 5). 
At the entrance of the binding pocket 
 
 
Figure 5. Representation of the binding mode of TFAH 10e 
(blue) in hAChE (PDB id: 4EY7, surface representation in gray) 
with seven structural water molecules (red) obtained by the Gold 
program. Distances are given in italic numbers in Å and were 
measured in PyMOL.[50] 
 
the feruloyl can be stabilized by forming a H-π interaction of 
2.8 Å with the π-system of His287. As it becomes visible in the 
surface representation of the AChE enzyme, the feruloyl part of 
the -acylaminocarboxamide backbone perfectly fits into the 
groove at the entrance of the binding site, thus inhibiting the 
PAS of AChE. This is firstly due to the presence of water 
molecules which force the tacrine to a different orientation 
compared to the pose without water. Furthermore, the linker 
adopts a more linear orientation in the docking pose with water. 
Lastly, in both presented poses, at least one of the aromatic 
rings supported by the -acylaminocarboxamide chain blocks 
the PAS. To predict the presence of structural water molecules 
is not straightforward, thus two possible modes of action – with 
structural water molecules and without – are presented. 
The predictive binding mode for the interaction of the 
ligand TFAH 10e with the target structure hBuChE is depicted in 
figure 6. The tacrine unit of the ligand is π–π stacked against the 
aromatic ring of Trp82 and of His438 and its protonated pyridine 
nitrogen atom is hydrogen-bonded to carbonyl group of His438. 
Other hydrophobic interactions are formed with Trp430, Tyr440, 
2.8 
Ser203 
His447 
Tyr72 
Trp286 
PAS 
His287 
Trp86 
2.8 
CAS 
Trp86 
Tyr449 
His447 
Tyr337 
Tyr341 
Val294 Ser293 
Trp286 
Phe297 
Tyr124 
Tyr72 
Val73 
Gly120 
Gly121 
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Trp82 
Tyr440 
Trp430 
Thr120 
Gly116 Gly117 
Asp70 
Pro285 
Tyr332 
Phe329 
Trp231 
His438 
Ser198 
Met437 and Gly439. This disposition in the active site is the 
same as the tacrine ligand adopts in the enzyme according to 
the crystallographic data. 
The hydrophobic 2’-chloro-6’-methylphenyl moiety was well fitted 
in a hydrophobic pocket made by Pro285, Thr284, Ala328 and 
Gly283. In addition, the methoxyphenol is π-stacked (T-shaped) 
against the aromatic ring of Phe329, while the hydroxyl group  
 
Figure 6. View A: Representation of the binding mode of 
compound TFAH 10e, as cyan stick, with hBuChE (PDB 
id: 4BDS). The key residues that interact with the 
molecule are depicted as thin sticks in orange. View B: 
2D diagram of the ligand-protein interactions (hydrogen 
bonds, as donor and acceptor, are represented with blue 
and green dashed lines, respectively). 
 
and the methoxy substituent are H-bonded to Ser198 side chain 
and to Gly117 main chain, respectively. Additionally, this 
substituent forms CH-π interactions with Trp231 and other 
hydrophobic interactions with Phe398 and Val288. Polar 
interactions are also observed with Thr284, Pro285 and Ser287.  
The tether link is fitted through hydrophobic and polar 
interactions with Ile69, Asn83, Gly116 and Thr120, and Asp70 
and Tyr332, respectively (Figure 6). For TFAH 10h, a similar 
binding mode is observed from docking simulations. However, 
the high flexibility of these ligands allows the formation of 
stacking interactions involving a different aromatic ring. Thus, 
the lowest binding energy for TFAH 10h implies stacking 
interactions of the benzyl moiety with Phe329, as the 
methoxyphenol group of TFAH 10e, while this one forms sigma-
π interactions with Ser287 and H-bonding, via oxygenated 
substituents, with Asn289. 
 
In silico ADMET analysis  
Various well known AChEI, such as ensaculine, donepezil, 
propidium, rivastigmine, and tacrine, have shown slight 
improvement in cognitive and memory disorders. However, 
nitrogen containing AChEI drugs have certain side effects and 
lower central nervous system (CNS) permeability. Thus, the new 
drugs for AD treatment should have a suitable CNS penetration 
profile and low side effects. Indeed, one of the most important 
requirements for a successful CNS drug is to penetrate and 
reach the therapeutic targets. 
To evaluate this aspect, key parameters related to ADMET 
properties,[51–53] with special emphasis on the requirements of 
the CNS, were calculated (Table 2S, Supporting Information). 
The calculated lipophilicity (expressed as logP) and molecular 
weight (MW) for this series violate the Lipinski’s rules for both 
parameters (logP<5, MW>500).[54] CNS drugs require more strict 
rules for a successful penetration to CNS. Thus, the optimal 
physicochemical properties for a compound targeting the CNS[55] 
were rationalized as a logP=2.8, a MW=305 g.mol-1, a 
TPSA=44.8 Å and a hydrogen-bond donor count=1. For the 
series under study, the predicted values fall out the appropriate 
ranges.  
Our estimations of blood-brain barrier (BBB) penetration 
suggest a moderate absorption to CNS for all the hybrids, but 
low for TFAHs 10e, 10l and 10n. In this sense, observations 
made by a team at Pfizer suggested that CNS penetration 
decreased as MW increased.[56] In addition, TFAHs 10l and 10n 
present the high values of TPSA. According to the computed 
values of brain penetration,[57] TFAHs 10a, 10b, 10c and 10f 
should be the best candidates of the series to act as CNS active 
compounds.  
Another important parameter to be considered for an oral drug 
is the intestinal permeability. On the basis of the models applied, 
all the structures show an adequate intestinal (Peff) and 
apparent Madin-Darby Canine Kidney (MDCK) permeability to 
be good candidates (Peff>0.1, MDCK>25), and should be well 
absorbed compounds (%HIA). In addition, a middle Caco-2 cell 
permeability is predicted.[58]  
Finally, the binding to plasma protein is a parameter which 
affects drug availability to the target receptor or enzyme. Indeed, 
the less bound a drug is, the more efficiently it can traverse cell 
membranes or diffuse to reach the site of action. The percent of 
drug bound with plasma proteins was estimated and the 
compounds were predicted to weakly bind to plasma proteins, 
so they will be available for diffusion or transport across cell 
membranes and thereby finally interact with the target. As 
previously observed,[56] plasma protein binding increased with 
MW. Regarding toxicity issues, in the drug development phase, 
an early evaluation of a potential for blocking the hERG (human 
ether-a-go-go related gene) channels is suggested to avoid 
a) 
b) 
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strong side effects in future clinical trials such as QT interval 
prolongation. According to results of our predictions, all the 
hybrids show hERG liability.[59] On other hand, none of the 
hybrids are predicted to induce carcinogenicity in chronic mouse 
studies. In addition, the models suggest that all molecules, 
except TFAHs 10m and 10n, present hepatotoxicity.[60] To sum 
up, the structures were predicted to have moderate to low brain 
penetration profiles, being 10a, 10b, 10c and 10f the hybrids 
with the best predicted BBB penetration within the TFAHs 
synthesized in this work. 
In order to confirm the virtual BBB predictions, next we 
carried out the in vitro Blood–Brain Barrier permeation assay of 
some selected TFAHs. 
 
In vitro Blood–Brain Barrier Permeation Assay 
 
Many methods have been performed to predict the BBB 
permeation of investigational drugs. Among them, the parallel 
artificial membrane permeation assays (PAMPA) have the 
advantage of predicting passive blood−brain barrier permeation 
with high success, high throughput, and reproducibility. In this 
work, brain penetration of TFAHs 10a-n was predicted using the 
in vitro PAMPA-BBB assay described by Di et al.,[61] and partially 
modified by Rodríguez-Franco et al. for assaying molecules with 
limited water-solubility.[62,16,63] The permeability of hybrids (Pe) 
through a lipid extract of porcine brain was determined during 2 
hours at room temperature by using PBS: ethanol (70:30) as 
solvent and results are gathered in table 6. In the same assay, 
11 commercial drugs of known CNS penetration were also 
tested and their values were compared to reported values, 
giving a good lineal correlation, Pe (exp.) = 1.48 Pe (bibl.) + 7.14 
(R2 = 0.93). From this equation and following the pattern 
established by Di et al. for BBB permeation prediction,[61] we can 
predict compounds as follow: cns + (high BBB permeation) if Pe 
(10-6 cm s-1) > 13.0; cns – (low BBB permeation) if Pe (10
-6 cm s-
1) < 10.0; and cns + / – (uncertain BBB permeation) if Pe (10
-6 
cm s-1) is between these values (Table 6). Best results for the 
CNS permeation were obtained for the 7-MEOTA derivatives, 
10m and 10n, bearing respectively the benzyl and naphtyl group. 
Very interestingly, the best predicted BBB penetration TFAHs 
10a, 10b, 10c and 10f showed no permeability on this assay. In 
the case of TFAH 10a, and not surprisingly, specific ex-vivo 
brain penetration study (see Experimental Part) was not 
observed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6. Permeability Values from the PAMPA-BBB Assay Pe (10
-6
 cm.s
-1
) of 
TFAHs 10a-n.
[a]
 
    PAMPA-BBB 
Compd. n R2 R1 Pe (10
-6
 cm s
-1
) Prediction 
10a 5 2’-Cl-6’-MeC6H3 H 6.5 ± 0.3 cns – 
10b 6 2’-Cl-6’-MeC6H3 H 6.1 ± 0.2 cns – 
10c 7 2’-Cl-6’-MeC6H3 H 7.6 ± 0.3 cns – 
10d 8 2’-Cl-6’-MeC6H3 H 11.0 ± 0.4 cns + / – 
10e 9 2’-Cl-6’-MeC6H3 H 16.1 ± 0.8 cns + 
10f 6 Bn H 6.6 ± 0.6 cns – 
10g 7 Bn H 7.2 ± 0.5 cns – 
10k 8 2’-Naphtyle H 27.6 ± 1.4 cns + 
10m 8 Bn OMe 13.2 ± 0.4 cns + 
10n 8 2’-Naphtyle OMe 61.5 ± 4.5 cns + 
[a] Results are the mean ± SD of three independent experiments. 
 
CONCLUSIONS 
 
From all the biological and physico-chemical results gathered in 
this study, we have identified TFAH (E)-3-(4-hydroxy-3-
methoxyphenyl)-N-(8-((7-methoxy-1,2,3,4-tetrahydroacridin-9-
yl)amino)octyl)-N-(2-(naphthalen-2-ylamino)-2-
oxoethyl)acrylamide (10n) as suitable multipotent TFAH for 
further development. TFAH 10n shows moderate and selective 
hBuChE inhibition (IC50= 68.2±3.9 nM), ability to penetrate into 
the CNS, strong antioxidant power (4.29, ORAC test), inhibition 
of A1-42 self-aggregation (65.6%) and surpasses by far the other 
TFAHs in the hepatotoxicity profile (59.4%, 1.72 less toxic than 
tacrine, at 1000 µᴍ), affording good neuroprotection capacity 
against toxic insults such as A1-40, A1-42, H2O2, and oligomycin 
A/rotenone, on SH-SY5Y cells, at 1 µᴍ. The power and 
selectivity of these TFAHs versus BuChE is worth of note as it is 
very well known that in patients with moderate to severe forms 
of AD, AChE levels are decreased, and BuChE activity is 
elevated,[64] suggesting that ACh hydrolysis in cholinergic 
synapses may largely occur via BuChE catalysis.[65] This 
suggests that specific inhibition of BuChE may be important in 
raising ACh levels and improving cognition in AD patients with 
moderate forms of AD.[66] 
To sum up, we think that the results reported here support 
and strengthen the interest on the development of new TFAHs 
derivatives as valuable multipotent drugs for the treatment and 
prevention of AD. We have also demonstrated and validated the 
use of the Ugi reaction for the discovery of new MTDLs for AD 
therapy. Thus, this study provides the basis for the future design 
of whole new MTDLs libraries having up to five 
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pharmacologically relevant scaffolds in one step via the Ugi 
reaction or its many variations.  
 
EXPERIMENTAL SECTION 
 
General methods for the synthesis: All reagents were pure 
analytical grade and used without further purification. All 
reactions were monitored by TLC using precoated silica gel 
aluminium plates (Macherey-Nagel) and visualized by UV light. 
Flash Column chromatographies were carried out using silica 
gel 60 (70-230 mesh, Macherey-Nagel). 1H and 13C (JMOD 
sequence) NMR spectra were acquired respectively at 300 MHz 
and 75 MHz on a Bruker AC300 spectrometer (Bruker BioSpin). 
Chemical shifts () are reported in parts per million (ppm) 
relative to the residual solvent signals and coupling constants (J) 
are reported in Hertz. The following abbreviations are used: s, 
singlet; bs, broad singlet; d, doublet; dd, doublet of doublet; t, 
triplet; q, quadruplet; quintuplet, quint.; m, multiplet. Infrared 
spectra were recorded on a Perkin-Elmer Spectrum 65 
spectrophotometer using an Attenuated Total Reflectance 
device ( in cm-1). High resolution mass spectra were obtained 
at Centre Commun de Spectrométrie de Masse, Lyon, France 
on a Bruker micrOTOF-Q II spectrometer (Bruker Daltonics) in 
positive ESI-TOF (electrospray ionization-time of flight). The 
TFAHs were found to be ≥ 95% pure by HPLC analysis using a 
Hitachi Lachrom Elite series instrument equipped with a L2400 
Lachrom Elite DAD detector and a Uptisphere ODB column (4.6 
mm x 100 mm, Ø= 3 μm). Peaks were detected at 210 nm and 
the system was operated at 25 °C with a flow rate of 2 mL/min. 
The mobile phase was an isocratic mixture of acetonitrile and 
water (1:1, v/v) containing 0.1% (w/v) monopotassium 
phosphate. 
 
General procedure for the synthesis of compounds 9a-f: 9-
Chlorotacrines (9a-f, 1.0 mmol, 1 equiv), alkylenediamine (3.0 
mmol, 3 equiv) and pentan-1-ol (3 mL) were reacted and heated 
to reflux for 18 h. The reaction was cooled to room temperature, 
diluted with CH2Cl2 (50 mL), and washed with a 10% (w/v) 
aqueous KOH solution (2x50 mL) and water (2x50 mL). The 
organic layer was dried over Na2SO4 and concentrated under 
reduced pressure to afford the crude product which was purified 
by flash column chromatography CH2Cl2/MeOH/aqueous 30% 
NH3 (7:3:0.1, v/v) to afford the products 9a-f. Analytical data of 
the tacrine linkers 9a-f are in good agreement with previously 
described data.[33] 
 
General procedure for the synthesis of TFAHs 10a-n: A 
solution of the corresponding N1-(1,2,3,4-tetrahydroacridin-9-
yl)alkane-1,n-diamine 9a-e or N1-(7-methoxy-1,2,3,4-
tetrahydroacridin-9-yl)alkane-1,8-diamine 9f (1.0 mmol) and 
paraformaldehyde (1.0 mmol) in MeOH/CH2Cl2 (7 mL, 3:1, v/v) 
was stirred for 1 h at room temperature. Ferulic acid (1.0 mmol) 
and the corresponding isocyanide (1.0 mmol) were then added, 
and the reaction was stirred 24h at room temperature. The 
mixture was subsequently concentrated under reduced pressure 
to dryness and the crude product was purified by flash column 
chromatography to afford the corresponding TFAHs. Note 
regarding the 1H and 13C spectra of TFAHs 10a-n: At 298 K, 
some Ugi adducts may appear as a mixture of conformers.  
 
(E)-N-(2-((2-Chloro-6-methylphenyl)amino)-2-oxoethyl)-3-(4-
hydroxy-3-methoxyphenyl)-N-(5-((1,2,3,4-tetrahydroacridin-
9-yl)amino)pentyl)acrylamide (10a): N1-(1,2,3,4-
tetrahydroacridin-9-yl)pentane-1,5-diamine (9a) (215 mg, 0.76 
mmol), paraformaldehyde (22 mg, 0.76 mmol), ferulic acid (147 
mg, 0.76 mmol) and 2-chloro-6-methylphenyl isocyanide (115 
mg, 0.76 mmol) were reacted in MeOH/CH2Cl2 (7 mL) according 
to the general procedure for the U-4CR. Flash column 
chromatography CH2Cl2/MeOH/aqueous 30% NH3 (92:8:0.1) 
afforded the TFAH 10a (90 mg, 19%) as an orange foam: 
Rf=0.18 (CH2Cl2/MeOH/aqueous 30% NH3 92:8:0.1); 
1H NMR 
(300 MHz, CD3OD): =8.09 and 8.04 (d, J=8.5 Hz, 1H), 7.74-
7.71 (m, 1H), 7.54 (d, J=6.2 Hz, 1H), 7.49 (d, J=6.2 Hz, 1H), 
7.35-7.27 (m, 1H), 7.24-7.21 (m, 1H), 7.15-7.06 (m, 3H), 7.01-
6.98 (m, 1H), 6.85 (d, J=15.2 Hz, 1H), 6.76 (t, J=8.5 Hz, 1H), 
4.43 (s, 1H), 4.31 (s, 1H), 3.83 and 3.77 (m, 3H), 3.64-3.50 (m, 
4H), 2.91 (m, 2H), 2.65-2.62 (m, 2H), 2.25-2.18 (m, 3H), 1.82 (m, 
4H), 1.67-1.60 (m, 4H), 1.48-1.40 (m, 2H); 13C NMR (75 MHz, 
CD3OD): =170.5, 170.3, 170.1, 157.9, 154.1, 150.8, 149.6, 
146.5, 145.1, 140.2, 139.9, 134.3, 133.7, 130.6, 130.3, 129.8, 
129.5, 128.4, 128.3, 128.2, 126.7, 125.2, 125.0, 124.8, 124.0, 
123.6, 120.7, 116.8, 115.3, 114.9, 112.2, 111.9, 56.6, 52.1, 51.3, 
50.7, 33.4, 32.0, 30.9, 30.0, 28.6, 26.0, 25.4, 25.2, 24.0, 23.5, 
19.0; HPLC: tR=1.84 min, 97.8%; HRMS ESI-TOF [M+H]
+ m/z 
calcd. for C37H41ClN4O4: 641.2889, found: 641.2881. 
 
 (E)-N-(2-((2-Chloro-6-methylphenyl)amino)-2-oxoethyl)-3-(4-
hydroxy-3-methoxyphenyl)-N-(6-((1,2,3,4-tetrahydroacridin-
9-yl)amino)hexyl)acrylamide (10b): N1-(1,2,3,4-
tetrahydroacridin-9-yl)hexane-1,6-diamine (9b) (206 mg, 0.69 
mmol), paraformaldehyde (21 mg, 0.69 mmol), ferulic acid (134 
mg, 0.69 mmol) and 2-chloro-6-methylphenyl isocyanide (97 mg, 
0.69 mmol) were reacted in MeOH/CH2Cl2 (7 mL) according to 
the general procedure for the U-4CR. Flash column 
chromatography CH2Cl2/MeOH/aqueous 30% NH3 (92:8:0.1) 
afforded the TFAH 10b (122 mg, 27%) as an orange foam: 
Rf=0.16 (CH2Cl2/MeOH/aqueous 30% NH3 92:8:0.1); 
1H NMR 
(300 MHz, CD3OD): =8.05 (t, J=8.0 Hz, 1H), 7.71 (d, J=8.0 Hz, 
1H), 7.51 (d, J=3.3 Hz, 1H), 7.46 (d, J=3.3 Hz, 1H), 7.35-7.28 (m, 
1H), 7.24-7.21 (m, 1H), 7.12-7.07 (m, 3H), 6.99 (t, J=8.0 Hz, 1H), 
6.84 (d, J=15.0 Hz, 1H), 6.77-6.71 (m, 1H), 4.42 (s, 1H), 4.29 (s, 
1H), 3.81 and 3.78 (s, 3H), 3.58-3.49 (m, 4H), 2.90 (m, 2H), 
2.66-2.62 (m, 2H), 2.23 and 2.12 (s, 3H), 1.82 (m, 4H), 1.61 (m, 
4H), 1.35-1.24 (m, 4H); 13C NMR (75 MHz, CD3OD): =170.4, 
170.2 (2C), 170.0, 158.4, 153.9, 150.9, 149.6, 147.1, 145.2, 
145.1, 140.1, 139.8, 134.3, 133.7,130.3, 129.7, 129.5, 128.4, 
128.3, 128.2, 127.3, 127.2, 125.0, 124.8, 124.7, 124.0, 123.6, 
121.0, 116.8, 116.7, 116.5, 115.3, 114.8, 112.2, 111.8, 56.6, 
52.0, 51.2, 50.8, 33.8, 32.2, 30.2, 28.7, 27.8, 27.5, 26.1, 24.1, 
23.6, 19.0; IR (ATR): max=3198, 2932, 2858, 1683, 1642, 1578, 
1511, 1452, 1423 cm-1, 1364; HPLC: tR=2.15 min, 96.7%; HRMS 
ESI-TOF [M+H]+ m/z calcd. for C38H44ClN4O4 : 655.3046, found: 
655.3031. 
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(E)-N-(2-((2-Chloro-6-methylphenyl)amino)-2-oxoethyl)-3-(4-
hydroxy-3-methoxyphenyl)-N-(7-((1,2,3,4-tetrahydroacridin-
9-yl)amino)heptyl)acrylamide (10c): N1-(1,2,3,4-
tetrahydroacridin-9-yl)heptane-1,7-diamine (9c) (206 mg, 0.69 
mmol), paraformaldehyde (21 mg, 0.69 mmol), ferulic acid (134 
mg, 0.69 mmol) and 2-chloro-6-methylphenyl isocyanide (97 mg, 
0.69 mmol) were reacted in MeOH/CH2Cl2 (7 mL) according to 
the general procedure for the U-4CR. Flash column 
chromatography CH2Cl2/MeOH/aqueous 30% NH3 (92:8:0.1) 
afforded the TFAH 10c (122 mg, 27%) as a yellow foam: 
Rf=0.25 (CH2Cl2/MeOH/aqueous 30% NH3 92:8:0.1); 
1H NMR 
(300 MHz, CD3OD): =8.05 (t, J=9.1 Hz, 1H), 7.71 (d, J=7.9 Hz, 
1H), 7.51 (d, J=4.9 Hz, 1H), 7.46 (d, J=4.9 Hz, 1H), 7.32-7.27 (m, 
1H), 7.22-7.20 (m, 1H), 7.11-7.08 (m, 3H), 6.99 (t, J=9.1 Hz, 1H), 
6.83 (d, J=15.1 Hz, 1H), 6.77-6.71 (m, 1H), 4.41 (s, 1H), 4.29 (s, 
1H), 3.79 (s, 3H), 3.57-3.46 (m, 4H), 2.90 (m, 2H), 2.62 (m, 2H), 
2.23 and 2.16 (m, 3H), 1.82 (m, 4H), 1.60-1.57 (m, 4H), 1.30 (m, 
6H); 13C NMR (75 MHz, CD3OD): =170.4, 170.2, 170.1, 170.0, 
158.4, 153.7, 151.0, 149.6, 147.2, 145.1, 140.1, 139.8, 134.2, 
133.6, 130.3, 129.7, 129.5, 128.4, 128.3, 128.1, 127.3, 125.0, 
124.7, 124.0, 123.6, 121.0, 116.8, 116.4, 115.2, 114.7, 112.2, 
111.8, 56.6, 52.0, 51.2, 50.8, 33.8, 32.3, 30.2, 28.7, 27.9, 27.7, 
26.1, 24.1, 23.6, 19.0; IR (ATR): max=3234, 2928, 2855, 1676, 
1642, 1567, 1511, 1421 cm-1, 1367; HPLC: tR=2.95 min, 99.3%; 
HRMS ESI-TOF [M+H]+ m/z calcd. for C39H46ClN4O4: 669.3202, 
found : 669.3182. 
(E)-N-(2-((2-Chloro-6-methylphenyl)amino)-2-oxoethyl)-3-(4-
hydroxy-3-methoxyphenyl)-N-(8-((1,2,3,4-tetrahydroacridin-
9-yl)amino)octyl)acrylamide (10d): N1-(1,2,3,4-
tetrahydroacridin-9-yl)octane-1,8-diamine (9d) (243 mg, 0.75 
mmol), paraformaldehyde (22 mg, 0.75 mmol), ferulic acid (134 
mg, 0.75 mmol) and 2-chloro-6-methylphenyl isocyanide (114 
mg, 0.75 mmol) were reacted in MeOH/CH2Cl2 (7 mL) according 
to the general procedure for the U-4CR. Flash column 
chromatography CH2Cl2/MeOH/aqueous 30% NH3 
CH2Cl2/MeOH/aqueous 30% NH3 (92:8:0.1) afforded the TFAH 
10d (138 mg, 27%) as an orange foam: Rf=0.30 
(CH2Cl2/MeOH/aqueous 30% NH3 92:8:0.1); 
1H NMR (300 MHz, 
CD3OD): =8.05 (t, J=8.0 Hz, 1H), 7.71 (d, J=8.0 Hz, 1H), 7.51 
(d, J=6.0 Hz, 1H), 7.47 (d, J=6.0 Hz, 1H), 7.31 (t, J=8.0 Hz, 1H), 
7.21 (m, 1H), 7.11-7.09 (m, 3H), 6.99 (t, J=9.2 Hz, 1H), 6.84 (d, 
J=15.1 Hz, 1H), 6.77-6.72 (m, 1H), 4.42 (s, 1H), 4.30 (s, 1H), 
3.80 (s, 3H), 3.59-3.46 (m, 4H), 2.91 (m, 2H), 2.64 (m, 2H), 2.23 
and 2.17 (m, 3H), 1.83 (m, 4H), 1.60-1.56 (m, 4H), 1.26 (m, 8H); 
13C NMR (75 MHz, CD3OD): =170.5, 170.1, 170.0, 158.5, 153.7, 
151.0, 149.6, 147.3, 145.1, 140.1, 139.8, 134.3, 134.1, 133.7, 
130.2, 129.7, 129.5, 128.4, 128.3, 128.1, 127.4, 125.0, 124.7, 
124.0, 123.6, 121.1, 116.9, 116.8, 116.5, 115.3, 114.8, 112.3, 
111.8, 56.6, 52.0, 51.2, 50.8, 33.9, 32.3, 30.3, 30.2, 28.8, 27.9, 
27.6, 26.1, 24.1, 23.7, 19.0; IR (ATR): max=3193, 2927, 2854, 
1676, 1642, 1578, 1511, 1452, 1365 cm-1; HPLC: tR=3.63 min, 
98.3%;  HRMS ESI-TOF [M+H]+ m/z calcd. for C40H48ClN4O4: 
683.3359, found: 683.3342. 
 
 (E)-N-(2-((2-Chloro-6-methylphenyl)amino)-2-oxoethyl)-3-(4-
hydroxy-3-methoxyphenyl)-N-(9-((1,2,3,4-tetrahydroacridin-
9-yl)amino)nonyl)acrylamide (10e): N1-(1,2,3,4-
tetrahydroacridin-9-yl)nonane-1,9-diamine (9e) (204 mg, 0.60 
mmol), paraformaldehyde (18 mg, 0.60 mmol), ferulic acid (117 
mg, 0.60 mmol) and 2-chloro-6-methylphenyl isocyanide (91 mg, 
0.60 mmol) were reacted in MeOH/CH2Cl2 (7 mL) according to 
the general procedure for the U-4CR. Flash column 
chromatography CH2Cl2/MeOH/aqueous 30% NH3 (92:8:0.1) 
afforded the TFAH 10e (78 mg, 19%) as an orange foam: 
Rf=0.29 (CH2Cl2/MeOH/aqueous 30% NH3 92:8:0.1); 
1H NMR 
(300 MHz, CD3OD): =8.06 (t, J=8.4 Hz, 1H), 7.74 (d, J=8.4 Hz, 
1H), 7.56-7.49 (m, 2H), 7.32 (t, J=8.4 Hz, 1H), 7.25-7.22 (m, 1H), 
7.15-6.98 (m, 4H), 6.86 (d, J=15.0 Hz, 1H), 6.80-6.74 (m, 1H), 
4.45 (s, 1H), 4.34 (s, 1H), 3.83 (s, 3H), 3.62-3.60 (m, 1H), 3.53-
3.44 (m, 3H), 2.93 (m, 2H), 2.66 (m, 2H), 2.26 and 2.20 (m, 3H), 
1.85 (m, 4H), 1.65-1.57 (m, 4H), 1.28-1.20 (m, 10H); 13C NMR 
(75 MHz, CD3OD): =170.5, 170.2, 170.0, 158.8, 153.6, 151.3, 
149.7, 147.6, 145.1, 140.1, 133.7, 130.3, 130.1, 129.7, 129.5, 
128.3, 128.0, 127.7, 124.9, 124.7, 124.0, 123.7, 121.2, 116.9, 
116.8, 116.6, 115.2, 114.7, 112.2, 111.8, 56.6, 52.0, 51.2, 50.8, 
34.0, 32.4, 30.5, 30.4, 28.0, 27.7, 26.2, 24.2, 23.7, 19.0; HPLC: 
tR=4.74 min, 96.9%; HRMS ESI-TOF [M+H]
+ m/z calcd. for 
C41H50ClN4O4: 697.3515, found: 697.3491. 
 
(E)-N-(2-(Benzylamino)-2-oxoethyl)-3-(4-hydroxy-3-
methoxyphenyl)-N-(6-((1,2,3,4-tetrahydroacridin-9-
yl)amino)hexyl)acrylamide (10f): N1-(1,2,3,4-tetrahydroacridin-
9-yl)hexane-1,6-diamine (9b) (200 mg, 0.67 mmol), 
paraformaldehyde (20 mg, 0.67 mmol), ferulic acid (130 mg, 
0.67 mmol) and benzyl isocyanide (82 µL, 0.67 mmol) were 
reacted in MeOH/CH2Cl2 (7 mL) according to the general 
procedure for the U-4CR. Flash column chromatography 
CH2Cl2/MeOH/aqueous 30% NH3 (92:8:0.1) afforded the TFAH 
10f (139 mg, 33%) as a yellow foam: Rf=0.25 
(CH2Cl2/MeOH/aqueous 30% NH3 92:8:0.1); 
1H NMR (300 MHz, 
CD3OD): =8.08-8.01 (m, 1H), 7.65 (m, 1H), 7.51 (m, 1H), 7.42 
(d, J=15.0 Hz, 1H), 7.31 (m, 1H), 7.20-7.08 (m, 5H), 7.00-6.85 
(m, 2H), 6.78 (d, J=15.0 Hz, 1H), 6.69-6.61 (m, 1H), 4.32 (m, 
2H), 4.18 (s, 1H), 4.07 (s, 1H), 3.73 and 3.70 (m, 3H), 3.49 (m, 
2H), 2.85 (m, 2H), 2.58-2.55 (m, 2H), 1.77 (m, 4H), 1.57-1.47 (m, 
4H), 1.28-1.20 (m, 6H); 13C NMR (75 MHz, CD3OD): =171.4, 
171.2, 169.9, 169.8, 157.1, 156.9, 156.8, 156.7, 154.7, 154.5, 
150.6, 149.4, 145.5, 145.4, 144.9, 140.0, 131.1, 129.6, 128.6, 
128.3, 128.2, 125.8, 125.6, 125.3, 125.2, 125.1, 123.7, 123.6, 
123.5, 120.1, 116.7, 115.7, 115.5, 115.3, 114.9, 112.2, 112.0, 
56.6, 52.2, 51.4, 50.7, 49.6, 44.3, 44.2, 44.0, 32.8, 32.1, 30.9, 
30.2, 28.6, 27.7, 27.4, 25.8, 23.8, 23.2; HPLC: tR=1.73 min, 
97.6%; HRMS ESI-TOF [M+H]+ m/z calcd. for C38H45N4O4: 
621.3435, found : 621.3435. 
 
(E)-N-(2-(Benzylamino)-2-oxoethyl)-3-(4-hydroxy-3-
methoxyphenyl)-N-(7-((1,2,3,4-tetrahydroacridin-9-
yl)amino)heptyl)acrylamide (10g): N1-(1,2,3,4-
tetrahydroacridin-9-yl)heptane-1,7-diamine (9c) (168 mg, 0.54 
mmol), paraformaldehyde (16 mg, 0.54 mmol), ferulic acid (105 
mg, 0.54 mmol) and benzyl isocyanide (66 µL, 0.67 mmol) were 
reacted in MeOH/CH2Cl2 (7 mL) according to the general 
procedure for the U-4CR. Flash column chromatography 
CH2Cl2/MeOH/aqueous 30% NH3 (92:8:0.1) afforded the TFAH 
10g (165 mg, 48%) as a yellow foam: Rf=0.30 
(CH2Cl2/MeOH/aqueous 30% NH3 9:1:0.1); 
1H NMR (300 MHz, 
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CD3OD): =8.13-8.06 (m, 1H), 7.75-7.73 (m, 1H), 7.57-7.47 (m, 
2 H), 7.40-6.96 (m, 8H), 6.89-6.65 (m, 2H), 4.39 (m, 2H), 4.23 (s, 
1H), 4.12 (s, 1H), 3.84 and 3.80 (m, 3H), 3.55-3.44 (m, 4H), 2.96 
(m, 2H), 2.72-2.70 (m, 2H), 1.89 (m, 4H), 1.62 (m, 4H), 1.34-
1.29 (m, 6H); 13C NMR (75 MHz, CD3OD): =171.4, 171.2, 169.9, 
169.8, 158.2, 153.8, 153.7, 151.3, 149.6, 146.9, 145.0, 140.0 
(2C), 139.9, 130.4, 129.6, 128.7, 128.6, 128.3 (2C), 127.9, 127.1, 
125.0, 124.7, 123.8, 123.6, 120.8, 116.9, 116.8, 116.3, 115.1, 
114.7, 112.2, 112.1, 56.6, 52.2, 51.4, 50.7, 44.3 (2C), 44.2, 44.0, 
33.6, 32.2, 30.1, 28.6, 28.3, 27.9, 27.6, 26.0, 24.0, 23.5, 23.4, 
23.3; IR (ATR): max=3284, 2928, 2855, 1642, 1579, 1511, 1452, 
1423 cm-1; HPLC: tR=1.63 min, 95.1%; HRMS ESI-TOF [M+H]
+ 
m/z calcd. for C39H47N4O4: 635.3592, found: 635.3577. 
 
 (E)-N-(2-(Benzylamino)-2-oxoethyl)-3-(4-hydroxy-3-
methoxyphenyl)-N-(8-((1,2,3,4-tetrahydroacridin-9-
yl)amino)octyl)acrylamide (10h): N1-(1,2,3,4-tetrahydroacridin-
9-yl)octane-1,8-diamine (9d) (176 mg, 0.54 mmol), 
paraformaldehyde (16 mg, 0.54 mmol), ferulic acid (105 mg, 
0.54 mmol) and benzyl isocyanide (66 µL, 0.67 mmol) were 
reacted in MeOH/CH2Cl2 (7 mL) according to the general 
procedure for the U-4CR. Flash column chromatography 
CH2Cl2/MeOH/aqueous 30% NH3 (92:8:0.1) afforded the TFAH 
10h (95 mg, 27%) as a yellow foam: Rf=0.31 
(CH2Cl2/MeOH/aqueous 30% NH3 9:1:0.1); 
1H NMR (300 MHz, 
CD3OD): =8.28-8.20 (m, 1H), 7.71 (m, 2H), 7.49-7.44 (m, 2 H), 
7.28-7.10 (m, 6H), 7.05-7.00 (m, 1H), 6.94-6.84 (m,1H), 6.74-
6.66 (m, 1H), 4.38-4.35 (m, 2H), 4.25 (s, 1H), 4.12 (s, 1H), 3.83-
3.71 (m, 5H), 3.58-3.53 (m, 1H), 3.48-3.44 (m, 1H), 3.19 (s, 1H), 
2.95 (m, 2H), 2.66 (m, 2H), 1.90 (m, 4H), 1.74-1.54 (m, 4H), 
1.33 (m, 8H); 13C NMR (75 MHz, CD3OD): =171.5, 171.3, 170.0 
(2C), 158.7, 153.7, 151.0, 149.7, 147.5, 145.0, 140.0, 130.2, 
129.8, 129.7, 128.7, 128.3, 128.1, 127.6, 124.9, 124.7, 123.8, 
123.6, 121.1, 116.9, 116.8, 116.6, 115.2 (2C), 114.8, 112.2, 
112.1, 56.6, 52.3, 51.4, 50.7, 44.4, 44.2, 34.0, 32.3, 30.3, 30.2, 
28.7, 27.9, 27.6, 26.2, 24.1, 23.7, 23.6, 23.5; IR (ATR): 
max=3233, 3059, 2927, 2854, 1638, 1584, 1514, 1452, 1427 cm
-
1; HPLC: tR=2.71 min, 95.7%; HRMS ESI-TOF [M+H]
+ m/z calcd. 
for C40H49N4O4: 649.3748, found : 649.3736. 
 
 (E)-3-(4-Hydroxy-3-methoxyphenyl)-N-(2-(naphthalen-2-
ylamino)-2-oxoethyl)-N-(6-((1,2,3,4-tetrahydroacridin-9-
yl)amino)hexyl)acrylamide (10i): N1-(1,2,3,4-tetrahydroacridin-
9-yl)hexane-1,6-diamine (9b) (200 mg, 0.67 mmol), 
paraformaldehyde (20 mg, 0.67 mmol), ferulic acid (130 mg, 
0.67 mmol) and naphthyl isocyanide (103 mg, 0.67 mmol) were 
reacted in MeOH/CH2Cl2 (7 mL) according to the general 
procedure for the U-4CR. Flash column chromatography 
CH2Cl2/MeOH/aqueous 30% NH3 (92:8:0.1) afforded the TFAH 
10i (143 mg, 32%) as a brownish foam: Rf=0.17 
(CH2Cl2/MeOH/aqueous 30% NH3 92:8:0.1); 
1H NMR (300 MHz, 
CD3OD): =8.17 (m, 1H), 8.09-8.02 (m, 1H), 7.71-7.64 (m, 4H), 
7.54-7.50 (m, 3H), 7.38-7.32 (m, 3H), 7.09-6.69 (m, 4H), 4.42 (s, 
1H), 4.26 (s, 1H), 3.79 (m, 2H), 3.67-3.60 (m, 1H), 3.52-3.48 (m, 
2H), 2.89 (m, 2H), 2.59 (m, 2H), 1.80 (m, 4H), 1.62-1.56 (m, 4H), 
1.37 (m, 6H); 13C NMR (75 MHz, CD3OD): =170.0, 169.8, 157.8, 
154.1, 150.8, 149.5, 146.5, 145.2, 144.9, 137.3, 135.3, 132.3, 
132.2, 130.6, 129.8, 129.7, 128.7, 128.6, 128.3, 128.2, 127.6, 
126.6, 126.4, 126.2, 126.1, 125.1, 125.0, 124.8, 123.9, 123.8, 
121.3, 121.2, 120.6, 118.0, 117.9, 116.8, 116.7, 116.2, 115.6, 
114.8, 112.2, 111.7, 56.6, 52.8, 52.3, 50.9, 49.6, 33.4, 32.1, 32.1, 
30.9, 30.3, 28.8, 27.9, 27.7, 27.4, 25.9, 23.9, 23.4, 23.3; IR 
(ATR): max=3269, 2928, 2855, 1690, 1640, 1583, 1561, 1503, 
1418, 1361 cm-1; HPLC: tR=3.31 min, 98.1%; HRMS ESI-TOF 
[M+H]+ m/z calcd. for C41H45N4O4: 657.3435, found: 657.3434. 
 
(E)-3-(4-Hydroxy-3-methoxyphenyl)-N-(2-(naphthalen-2-
ylamino)-2-oxoethyl)-N-(7-((1,2,3,4-tetrahydroacridin-9-
yl)amino)heptyl) acrylamide (10j): N1-(1,2,3,4-
Tetrahydroacridin-9-yl)heptane-1,7-diamine (9c) (200 mg, 0.64 
mmol), paraformaldehyde (19 mg, 0.64 mmol), ferulic acid (124 
mg, 0.64 mmol) and naphthyl isocyanide (98 mg, 0.64 mmol) 
were reacted in MeOH/CH2Cl2 (7 mL) according to the general 
procedure for the U-4CR. Flash column chromatography 
CH2Cl2/MeOH/aqueous 30% NH3 (92:8:0.1) afforded the TFAH 
10j (131 mg, 30%) as an orange-brownish foam: Rf=0.19 
(CH2Cl2/MeOH/aqueous 30% NH3 92:8:0.1); 
1H NMR (300 MHz, 
CD3OD): =8.17 (m, 1H), 8.04 (m, 1H), 7.69 (m, 4H), 7.53-7.50 
(m, 3H), 7.35-7.32 (m, 3H), 7.09-6.68 (m, 4H), 4.42 (s, 1H), 4.27 
(s, 1H), 3.80 and 3.67 (s, 3H), 3.60 (m, 1H), 3.47 (m, 3H), 2.90 
(m, 2H), 2.61 (m, 2H), 1.82 (m, 4H), 1.62-1.56 (m, 4H), 1.30-
1.26 (m, 6H); 13C NMR (75 MHz, CD3OD): =170.0, 169.8, 157.5, 
154.2, 150.8, 149.6, 146.2, 145.2, 144.8, 144.8, 144.7, 137.3, 
136.5, 135.3, 132.2, 130.8, 130.7, 129.7, 128.7, 128.2, 127.6, 
126.6, 126.4, 126.3, 126.2, 125.2, 125.0, 124.6, 123.9, 123.6, 
121.3, 120.4, 120.2, 118.0, 117.9, 117.7, 116.8, 116.4, 116.0, 
115.6, 114.8, 113.4, 113.2, 112.3, 111.7, 56.6, 52.8, 52.3, 51.0, 
33.3, 32.1, 30.9, 30.2, 29.3, 27.9, 27.7, 25.9, 23.9, 23.4, 23.3; IR 
(ATR): max=3280, 2927, 2854, 1690, 1639, 1583, 1560, 1503, 
1432, 1361 cm-1; HPLC: tR=4.02 min, 95.6%; HRMS ESI-TOF 
[M+H]+ m/z calcd. for C42H47N4O4: 671.3592, found: 671.3580. 
 
 (E)-3-(4-Hydroxy-3-methoxyphenyl)-N-(2-(naphthalen-2-
ylamino)-2-oxoethyl)-N-(8-((1,2,3,4-tetrahydroacridin-9-
yl)amino)octyl) acrylamide (10k): N1-(1,2,3,4-
tetrahydroacridin-9-yl)octane-1,8-diamine (9d) (200 mg, 0.61 
mmol), paraformaldehyde (18 mg, 0.61 mmol), ferulic acid (118 
mg, 0.61 mmol) and naphthyl isocyanide (93 mg, 0.61 mmol) 
were reacted in MeOH/CH2Cl2 (7 mL) according to the general 
procedure for the U-4CR. Flash column chromatography 
CH2Cl2/MeOH/aqueous 30% NH3 (92:8:0.1) afforded the TFAH 
10k (74 mg, 18%) as an orange-brownish foam: Rf=0.32 
(CH2Cl2/MeOH/aqueous 30% NH3 92:8:0.1); 
1H NMR (300 MHz, 
CD3OD): =8.20-8.18 (m, 1H), 8.08-8.04 (m, 1H), 7.75-7.68 (m, 
4H), 7.56-7.49 (m, 3H), 7.40-7.34 (m, 3H), 7.14-6.70 (m, 4H), 
4.44 (s, 1H), 4.29 (s, 1H), 3.83 and 3.69 (s, 3H), 3.64-3.59 (m, 
1H), 3.50-3.45 (m, 3H), 2.93 (m, 2H), 2.65 (m, 2H), 1.85 (m, 4H), 
1.65-1.56 (m, 4H), 1.27 (m, 8H); 13C NMR (75 MHz, CD3OD): 
=170.1, 169.9, 154.0, 150.8, 150.1, 149.6, 146.9, 145.2, 144.8, 
135.4, 132.3, 130.5, 129.8, 129.7, 129.6, 128.7, 128.3, 127.6, 
127.0, 126.1, 125.1, 124.8, 123.6, 121.3, 121.3, 120.9, 118.2, 
118.0, 116.8, 116.7, 116.4, 115.7, 114.9, 112.3, 111.7, 56.6, 
52.8, 52.2, 51.0, 33.6, 32.2, 30.3, 28.8, 27.8, 27.6, 26.0, 24.1, 
23.6, 23.5; IR (ATR): max=3200, 2928, 2856, 1689, 1638, 1560, 
1504, 1431, 1352; HPLC: tR=5.57 min, 98.9%;  HRMS ESI-TOF 
[M+H]+ m/z calcd. for C43H49N4O4: 685.3748, found: 685.3744. 
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(E)-N-(2-((2-Chloro-6-methylphenyl)amino)-2-oxoethyl)-3-(4-
hydroxy-3-methoxyphenyl)-N-(8-((7-methoxy-1,2,3,4-
tetrahydroacridin-9-yl)amino)octyl)acrylamide (10l): N1-(7-
Methoxy-1,2,3,4-tetrahydroacridin-9-yl)octane-1,8-diamine (9f) 
(202 mg, 0.57 mmol), paraformaldehyde (17 mg, 0.57 mmol), 
ferulic acid (110 mg, 0.57 mmol) and 2-chloro-6-methylphenyl 
isocyanide (86 mg, 0.57 mmol) were reacted in MeOH/CH2Cl2 (7 
mL) according to the general procedure for the U-4CR. Flash 
column chromatography with CH2Cl2/MeOH/aqueous 30% NH3 
(92:8:0.1) afforded the TFAH 10l (64 mg, 16%) as a brownish 
foam: Rf=0.20 (CH2Cl2/MeOH/aqueous 30% NH3 92:8:0.1); 
1H 
NMR (300 MHz, CD3OD): =7.67 (d, J=9.0 Hz, 1H), 7.52 (d, 
J=15.2 Hz, 1H), 7.36 (d, J=7.1 Hz, 1H), 7.28-7.21 (m, 2H), 7.18-
7.12 (m, 3H), 7.03 (t, J=9.0 Hz, 1H), 6.91-6.81 (m, 1H), 6.76 (d, 
J=8.1 Hz, 1H), 4.46-4.32 (m, 2H), 3.88-3.72 (m, 6H), 3.63-3.40 
(m, 4H), 2.93 (m, 2H), 2.73-2.71 (m, 2H), 2.26 and 2.20 (s, 3H), 
1.86 (m, 4H), 1.68-1.59 (m, 4H), 1.31-1.26 (m, 8H); 13C NMR (75 
MHz, CD3OD): =172.6, 170.5, 157.8, 156.7, 152.8, 150.7, 
149.6, 145.1, 143.1, 140.1, 136.2, 134.3, 133.7, 130.4, 130.3, 
129.8, 129.7 (2C), 129.5, 129.2, 129.1, 128.4 (2C), 124.3, 124.0, 
123.8, 123.6, 122.4, 122.3, 118.1, 118.0, 116.8, 116.7, 116.3, 
115.4, 115.0, 113.2, 112.3, 111.9, 103.2, 56.6, 56.3, 51.6, 51.2, 
50.8, 33.8, 32.4, 30.4, 30.4, 30.2, 28.0, 27.7, 27.6, 26.4, 24.2, 
23.8, 23.7, 19.0; IR (ATR): max 3234, 2928, 2855, 1679, 1625, 
1581, 1505, 1452, 1429 cm-1; HPLC: tR=4.10 min, 95.6%; HRMS 
ESI-TOF [M+H]+ m/z calcd. for C41H50ClN4O5: 713.3464, found: 
713.3471. 
 
(E)-N-(2-(Benzylamino)-2-oxoethyl)-3-(4-hydroxy-3-
methoxyphenyl)-N-(8-((7-methoxy-1,2,3,4-tetrahydroacridin-
9-yl)amino)octyl)acryl amide (10m): N1-(7-Methoxy-1,2,3,4-
tetrahydroacridin-9-yl)octane-1,8-diamine (9f) (202 mg, 0.57 
mmol), paraformaldehyde (17 mg, 0.57 mmol), ferulic acid (110 
mg, 0.57 mmol) and benzyl isocyanide (70 µL, 0.57 mmol) were 
reacted in MeOH/CH2Cl2 (7 mL) according to the general 
procedure for the U-4CR. Flash column chromatography with 
CH2Cl2/MeOH/aqueous 30% NH3 (92:8:0.1) afforded the TFAH 
10m (97 mg, 25%) as a yellow foam: Rf=0.23 
(CH2Cl2/MeOH/aqueous 30% NH3 98:2:0.1); 
1H NMR (300 MHz, 
CD3OD): =7.60 (d, J=9.0 Hz, 1H), 7.46-7.39 (m, 1H), 7.28-7.25 
(m, 1H), 7.21-7.19 (m, 2H), 7.16-7.11 (m, 3H), 7.07-7.05 (m, 1H), 
7.02 (m, 1H), 6.97-6.93 (m, 1H), 6.88-6.59 (m, 2H), 4.31 and 
4.29 (s, 2H), 4.16 (s, 1H), 4.06 (s, 1H), 3.79-3.68 (m, 6H), 3.46-
3.41 (m, 2H), 3.37-3.26 (m, 2H), 2.84 (m, 2H), 2.62-2.60 (m, 2H), 
1.76 (m, 4H), 1.48 (m, 4H), 1.17 (m, 8H); 13C NMR (75 MHz, 
CD3OD): =171.4, 171.2, 169.9 (2C), 157.7, 156.6, 152.7, 151.0, 
150.9, 149.6, 145.0, 143.1, 140.0, 139.9, 129.6, 129.1, 128.6, 
128.3, (2C), 128.1, 123.8, 123.6, 122.3, 122.2, 117.9, 116.9, 
116.8, 115.2, 114.8, 112.2, 112.1, 103.2, 56.6, 56.2, 52.2, 51.4, 
50.7, 44.3, 44.2, 44.0, 33.8, 32.4, 30.4, 30.3, 30.3, 30.2, 28.7, 
28.0, 27.6, 26.3, 24.2, 23.8; IR (ATR): max=3282, 2927, 2854, 
1643, 1581, 1511, 1453, 1428 cm-1; HPLC: tR=3.37 min, 96.0%; 
HRMS ESI-TOF [M+H]+ m/z calcd. for C41H51N4O5: 679.3854, 
found : 679.3868. 
 
(E)-3-(Hydroxy-3-methoxyphenyl)-N-(8((7-methoxy-1,2,3,4-
tetrahydroacridin-9-yl)amino)octyl)-N-(2-naphthalen-2-
ylamino)2-oxoethyl)acrylamide (10n): N1-(7-Methoxy-1,2,3,4-
tetrahydroacridin-9-yl)octane-1,8-diamine (9f) (209 mg, 0.59 
mmol), paraformaldehyde (18 mg, 0.59 mmol), ferulic acid (114 
mg, 0.59 mmol) and naphthyl isocyanide (90 mg, 0.59 mmol) 
were reacted in MeOH/CH2Cl2 (7 mL) according to the general 
procedure for the U-4CR. Flash column chromatography with 
CH2Cl2/MeOH/aqueous 30% NH3 (92:8:0.1) afforded the TFAH 
10n (74 mg, 18%) as a brownish foam: Rf=0.30 
(CH2Cl2/MeOH/aqueous 30% NH3 92:8:0.1); 
1H NMR (300 MHz, 
CD3OD): =8.18 (m, 1H), 7.75-7.63 (m, 4H), 7.55-7.48 (m, 2H), 
7.38-7.29 (m, 3H), 7.24-7.18 (m, 1H), 7.11-6.67 (m, 4H), 4.42-
4.17 (m, 2H), 3.85-3.67 (m, 6H), 3.61-3.33 (m, 4H), 2.89 (m, 2H), 
2.67-2.65 (m, 2H), 1.83 (m, 4H), 1.62-1.55 (m, 4H), 1.32-1.25 (m, 
8H); 13C NMR (75 MHz, CD3OD): =170.0, 169.8, 157.8, 156.3 
(2C), 152.9, 150.8, 149.6, 149.0, 145.2, 144.8, 137.3, 136.5, 
135.3, 132.2, 129.8, 129.7, 128.9, 128.8, 128.7, 128.6, 128.3, 
127.6 (2C), 126.1, 124.6, 123.8, 123.6, 122.3, 122.2, 121.3, 
121.2, 121.1, 120.2, 118.0, 117.9, 116.8, 116.6, 116.2, 114.8, 
113.3, 113.2, 112.3, 111.7, 103.3, 56.6, 56.3, 52.3, 51.7, 51.0, 
33.6, 33.6, 32.4, 30.4, 30.3, 28.0, 27.7, 27.6, 26.3, 24.1, 23.7; IR 
(ATR): max=3286, 2928, 2854, 1690, 1627, 1583, 1560, 1503, 
1451, 1430 cm-1; HPLC: tR=6.53 min, 97.4%;  HRMS ESI-TOF 
[M+H]+ m/z calcd. for C44H51N4O5: 715.3854, found: 715.3830. 
 
Cell culture 
 
In vitro toxicity of TFAHs 10a-n in HepG2 cells  
The HepG2 cell line was kindly provided by IdiPAZ Institute for 
Health Research (Madrid, Spain). The cells were cultured in 
Eagle´s minimum essential medium (EMEM) supplemented with 
15 nonessential amino acids, 1 mM sodium pyruvate, 10% heat-
inactivated fetal bovine serum (FBS), 100 units/mL penicillin, 
and 100 µg/mL streptomycin (reagents from Invitrogen, Madrid, 
Spain). Cultures were seeded into flasks containing 
supplemented medium and maintained at 37 ºC in a humidified 
atmosphere of 5% CO2 and 95% air. Culture media were 
changed every 2 days. Cells were sub-cultured after partial 
digestion with 0.25% trypsin-EDTA. For assays, HepG2 cells 
were subcultured in 96-well plates at a seeding density of 1x105 
cells per well. When the HepG2 cells reached 80% confluence, 
the medium was replaced with fresh medium containing 1–1000 
µᴍ compounds or 0.1% DMSO as a vehicle control. The cell 
viability was determined by MTT assay. The absorption was 
measured by a well plate reader at 540 nm. All compounds were 
dissolved in pure DMSO, but the final DMSO concentration (1-
1000 µᴍ) was 0.1% in culture medium 
Effect of TFAHs 10a-n on O/R and H2O2-induced oxidative 
cell damage in SH-SY5Y cells 
Human dopaminergic neuroblastoma SH-SY5Y cells were 
maintained in a 1:1 mixture of Nutrient Mixture F-12 and Eagle´s 
minimum essential medium (EMEM) supplemented with 15 
nonessential amino acids, sodium pyruvate (1 mᴍ), 10% heat-
inactivated FBS, 100 units/ml penicillin, and 100 µg/ml 
streptomycin. Cultures were seeded into flasks containing 
supplemented medium and maintained at 37 ºC in a humidified 
atmosphere of 5% CO2 and 95% air. For assays, SH-SY5Y cells 
were subcultured in 96-well plates at a seeding density of 8x104 
cells per well for 2 d. Cells were co-incubated with H2O2 (300 µᴍ) 
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or oligomycin A (10 µᴍ)/rotenone (30 µᴍ) (O/R) for 24 h to 
induce oxidative stress at several concentrations of test 
compounds in F-12/EMEM with 1% FBS. A vehicle group 
containing 0.1% dimethyl sulfoxide (DMSO) was employed in 
parallel for each experiment. All SH-SY5Y cells used in this 
study were used at a low passage number (<13). The cell 
viability was determined by MTT assay. The absorption was 
measured by a well plate reader at 540 nm. 
Effects of TFAHs 10a-n on A1-40 and A1-42 peptides-
induced neurotoxicity in SH-SY5Y cells 
Lyophilized A1-40 and A1-42 peptides (Abcam, MA, USA) were 
reconstituted in sterile water at a concentration of 2 mᴍ and 
keep at 80 ºC until use. Aliquots were diluted with a culture 
medium to achieve a final concentration of 30 µᴍ and then 
incubated at 37 ºC for 72 h to form aggregated amyloid. For 
assays, SH-SY5Y cells were sub-cultured into a 96 well plate for 
24 h. Then, the cells were incubated with A1-40 and A1-42 
peptides (30 ᴍ) without or with various concentrations of the 
test compound for 24 h. Cell viability was determined by staining 
the cells with 0.5 mg/ml of MTT assay. The absorption was 
measured by a well plate reader at 540 nm. 
Measurement of cell viability  
MTT reduction was performed as described[38] for the HepG2 
cell line. This assay is based on the ability of the mitochondrial 
enzyme succinate dehydrogenase to convert the yellow water-
soluble tetrazolium salt (MTT) into formazan crystals in 
metabolically active cells. Briefly, 50 µL of the MTT labeling 
reagent, at a final concentration of 0.5 mg/ml, was added. After 
incubation for 2 h, in a humidified incubator at 37 ºC with 5% 
CO2 and 95% air (v/v), the supernatant was removed, the 
obtained purple formazan product was re-suspended in 100 μL 
of Dimethyl Sulfoxide (DMSO). Colorimetric determination of 
MTT reduction was measured in an ELISA microplate reader at 
540 nm. Control cells treated with EMEM were taken as 100% 
viability.  
 
Inhibition of cholinesterases 
 
Inhibition of EeAChE and eqBuChE  
Inhibitory activity assessment of the TFAHs on ChEs was 
performed following the spectrophotometric method of Ellman[41] 
using purified AChE from Electrophorus electricus (Type V-S, 
Sigma-Aldrich) or BuChE from horse serum (lyophilized powder, 
Sigma-Aldrich). Enzymes were first dissolved in 0.1 ᴍ phosphate 
buffer (pH= 8.0) and then aliquoted in small vials. Compounds 
stock solutions in DMSO (10 mᴍ) were further diluted with 
DMSO to prepare nine serial dilutions of each compound. The 
reaction occurs in a final volume of 3 mL of a 0.1 M phosphate-
buffered solution at pH= 8.0, containing 5,5’-dithiobis-2-
nitrobenzoic acid (DTNB, 2625 µL, 0.35 mᴍ, final concentration), 
EeAChE (29 µL, 0.035 U/mL, final concentration) or eqBuChE 
(60 µL, 0.05 U/mL, final concentration), tested compound (3 µL, 
0.001-1000 nᴍ, final concentrations) and 1% w/v Bovine 
Albumin Serum phosphate-buffered (pH=8.0) solution (BSA, 60 
µL). Inhibition curves were built by pre-incubating this blend at 
room temperature with nine concentrations of each compound 
for 10 min. A control with no compound was always present to 
determine the percent of enzymatic activity. After this pre-
incubation period, acetylthiocholine iodide (105 µL, 0.35 mᴍ, 
final concentration) or butyrylthiocholine iodide (150 µL, 0.5 mᴍ, 
final concentration) was added, allowing 15 min of additional 
incubation time, where the DTNB produces the yellow anion 5-
thio-2-nitrobenzoic acid as an indicator of enzymatic activity. 
After 15 min, absorbances were measured at 412 nm in a 
spectrophotometer plate reader (iEMS Reader MF, Labsystems). 
Color generation would be reduced as the compound inhibits the 
enzymes. IC50 values were calculated graphically at the 
concentration of compound that decreases 50% of the 
enzymatic activity by using a nonlinear regression method (four 
parameter logistic method). Data are expressed as means ± 
SEM of at least three different experiments in quadruplicate. 
Inhibition of hAChE and hBuChE 
The capacity of the new derivatives to inhibit cholinesterases 
activity was assessed using the Ellman’s method.[41] Initial rate 
assays were performed at 37 °C with a Jasco V-530 double 
beam Spectrophotometer by following the rate of increase in the 
absorbance at 412 nm for 210 s. AChE stock solution was 
prepared by dissolving human recombinant AChE (E.C.3.1.1.7) 
lyophilized powder (Sigma, Italy) in 0.1 M phosphate buffer (pH= 
8.0) containing Triton X-100 0.1%. Stock solution of BuChE (E.C. 
3.1.1.8) from human serum (Sigma, Italy) was prepared by 
dissolving the lyophilized powder in an aqueous solution of 
gelatine 0.1%. The final assay solution consisted of a 0.1 ᴍ 
phosphate buffer (pH= 8.0), with the addition of 340 µᴍ 5,5'-
dithio-bis(2-nitrobenzoic acid), 0.02 unit/mL of human 
recombinant AChE, or BuChE from human serum and 550 µᴍ of 
substrate (acetylthiocholine iodide, ATCh or butyrylthiocholine 
iodide, BTCh, respectively). Stock solutions of tested 
compounds were prepared in methanol. Five different 
concentrations of inhibitor were selected in order to obtain 
inhibition of the enzymatic activity comprised between 20% and 
80%. Assays were carried out with a blank containing all 
components except AChE or BuChE in order to account for the 
non-enzymatic reaction. Assay solutions (with and without 
inhibitor) were preincubated for 20 min at 37 °C before the 
addition of substrate. The reaction rates were compared and the 
percent inhibition due to the presence of increasing 
concentrations of inhibitor was calculated. Each concentration 
was analyzed in duplicate, and IC50 values were determined 
graphically from log concentration–% inhibition curves 
(GraphPad Prism 4.03 software, GraphPad Software Inc.). 
 
Oxygen Radical Absorbance Capacity Assay  
The radical scavenging capacity of the TFAHs was determined 
by the ORAC-FL method using fluorescein as a fluorescent 
probe.[42,43] (±)-6-Hydroxy-2,5,7,8-tetramethylchromane-2-
carboxylic acid (Trolox), fluorescein (FL) and 2,2’-
azobis(amidinopropane) dihydrochloride (AAPH) were 
purchased from Sigma-Aldrich. A Varioskan Flash plate reader 
with built-in injectors (Thermo Scientific) was used. The reaction 
was carried out at 37 °C in 75 mᴍ phosphate buffer (pH= 7.4), 
and the final volume reaction mixture was 200 µL. The tested 
compounds and Trolox standard were dissolved in DMSO to 10 
mᴍ and further diluted in 75 mᴍ phosphate buffer (pH= 7.4). The 
final concentrations were 0.1-1 µᴍ for the tested compounds and 
1-8 µᴍ for Trolox standard. The blank was composed of 120 µL 
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of FL, 60 µL of AAPH and 20 µL of phosphate buffer (pH=7.4) 
and was added in each assay. In a black 96-well microplate 
(Nunc), antioxidant (20 µL) and fluorescein (FL, 120 µL, final 
concentration of 70 nᴍ) were incubated for 15 min at 37 °C. 
Then, 2,2’-azobis(amidinopropane) dihydrochloride (AAPH, 60 
µL, final concentration of 40 mᴍ) solution was added rapidly 
using the built-in injector. The fluorescence was measured every 
minute for 60 min at 485 nm (excitation wavelength) and 535 nm 
(emission wavelength). The microplate was automatically 
shaken prior to each reading. All the reactions were made in 
triplicate and at least three different assays were performed for 
each sample. Antioxidant curves (fluorescence versus time) 
were first normalized to the curve of the blank (without 
antioxidant) and then, the area under the fluorescence decay 
curve (AUC) was calculated as: AUC=1+ sum(fi/f0), Where f0 is 
the initial fluorescence reading at 0 min and fi is the 
fluorescence value at time i.  
The net AUC corresponding to a sample was calculated as 
follows: Net AUC=AUCantioxidant – AUCblank. 
Regression equations were calculated by plotting the net AUC 
against the antioxidant concentration. The ORAC value was 
obtained by dividing the slope of the latter curve between the 
slope of the Trolox curve obtained in the same assay. Final 
ORAC values were expressed as µmol of Trolox equivalent/µmol 
of TFAH. Data are expressed as means ±SD. 
 
Kinetic inhibition studies  
To estimate the mode of inhibition of TFAH 10h, Lineweaver-
Burk double reciprocal plots were constructed at relatively low 
concentration of substrate (0.11-0.56 µᴍ). The plots were 
assessed by a weighted least square analysis that assumed the 
variance of v to be a constant percentage of v for the entire data 
set. Data analysis was performed with GraphPad Prism 4.03 
software (GraphPad Software Inc.). Calculation of the inhibitor 
constant (Ki) value was carried out by re-plotting slopes of lines 
from the Lineweaver-Burk plot versus the inhibitor concentration 
and Ki was determined as the intersect on the negative x-axis. 
K’i (dissociation constant for the enzyme-substrate-inhibitor 
complex) value was determined by plotting the apparent 1/vmax 
versus inhibitor concentration.[67]  
 
Inhibition of A1-42 self-aggregation 
1,1,1,3,3,3-Hexafluoro-2-propanol (HFIP) pre-treated A1-42 
samples (Bachem AG, Switzerland) were resolubilized with a 
MeCN/Na2CO3/NaOH (48.4/48.4/3.2) mixture to have a stable 
stock solution ([A1-42]=500 µᴍ).
[44] Experiments were performed 
by incubating the peptide in 10 mᴍ phosphate buffer (pH=8.0) 
containing 10 mᴍ NaCl, at 30 °C for 24 h (final A 
concentration=50 ᴍ) with and without inhibitor (50 µᴍ). The 
inhibitor was dissolved in methanol and diluted in the assay 
buffer. Blanks containing inhibitor and ThT were also prepared 
and evaluated to account for quenching and fluorescence 
properties. To quantify amyloid fibril formation, the ThT 
fluorescence method was used.[68,69] After incubation, samples 
were diluted to a final volume of 2.0 mL with 50 µᴍ glycine-
NaOH buffer (pH= 8.5) containing 1.5 µᴍ ThT. A 300-seconds-
time scan of fluorescence intensity was carried out (exc=446 
nm; em=490 nm), and values at plateau were averaged after 
subtracting the background fluorescence of 1.5 µᴍ ThT solution. 
The fluorescence intensities were compared and the % inhibition 
was calculated.  
 
Docking simulations 
The geometry of the ligands were optimized using the ab initio 
quantum chemistry program Gaussian 09 and the B3LYP/3-
21G* basis set. A set of atom-centred RHF 6-31G* charges was 
then obtained by using the RESP methodology.[70] The 
crystallographic structure of the acetylcholinesterase with 
sequence from Electrophorus electricus was retrieved from the 
Protein Data Bank (PDB code: 1C2B)[71] as target protein. 
Missing atoms were reconstructed with SwissPDB Viewer 
4.1.0.[72] The docking experiments were carried out using the 
Lamarckian genetic algorithm implemented in the AutoDock 4.2 
program.[73] A box encompassing both the CAS and the PAS site 
was defined for the exploration of possible binding modes. A 
volume for exploration was defined in the shape of a three-
dimensional cubic grid (60 x 74 x 60 Å3) at a resolution of 0.3 Å 
and centered on the gorge that enclosed the regions that are 
known to make up the inhibitors binding pockets and modes. 
Affinity grid files were generated using the auxiliary program 
AutoGrid. At each grid point, the receptor’s atomic affinity 
potentials for carbon, oxygen, nitrogen, chloro and hydrogen 
atoms present in the ligand were precalculated for rapid intra- 
and intermolecular energy evaluation of the docking solution. 
Different conformers of the ligands were docked by randomly 
changing the torsion angles and overall orientation of the 
molecule. The receptor residues Trp286, Tyr124, Tyr337, Tyr72, 
Asp74, Thr75, Trp86, and Tyr341 were selected to keep flexible 
during docking simulation with the AutoTors module. The 
program searched until a maximum of 100 conformations and 
the procedure was repeated 100 times (runs). After docking, the 
100 solutions were clustered in groups with RMSD less than 1.5 
Å. The clusters were ranked by the lowest energy representative 
of each cluster. For all other parameters, the default values were 
used with AutoDock Tools. Due to the absence of X-ray 
structure of eqBuChE, a homology model was used to 
rationalize experimental data. To this end, the automated 
homology-modelling SWISS-MODEL program performed the 
modelling of the 3D structure.[72] The three-dimensional structure 
of eqBuChE was created (UniProt Q9N1N9, modelled residue 
range: 32-562) based on the crystal structure of hBuChE (PDB: 
2PM8).[74] Docking calculations were performed following the 
same protocol described above for EeAChE. Additionally, we 
performed docking simulations with the crystallographic 
structure of the hBuCHE in complex with tacrine as protein 
target (PDB code: 4BDS).[46] The results revealed that the 
tacrine moiety of the TFAH 10b occupies the same position that 
was observed in the original complex with tacrine (RMSD of 0.5 
Ǻ). Moreover, the ligand binding pose is equivalent to that found 
for the docking study with the modeled 3D structure of eqBuChE. 
The same docking protocol was applied for the binding studies 
of TFAHs 10e and 10h with the structure of human acetyl- (PDB 
code: 4EY7)[45] and butyrylcholinesterase (PDB code: 4BDS)[46] 
as target proteins. Analogously, the docking experiments were 
carried out using the Lamarckian genetic algorithm implemented 
in the AutoDock 4.2 program. 
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The docking method with the inclusion of seven structural water 
molecules was performed with the program Gold v.5.2 according 
to the method published by Darras et al.[49,75] In preliminary 
docking runs the tacrine showed hydrogen bond interactions to 
the catalytic Ser203. Thus, a mild hydrogen bond constraint was 
placed on the hydroxyl oxygen to obtain an optimized binding 
pose. The top scored pose is shown in figure 5. Distances were 
measured between heavy atoms or between the heavy atom 
and the geometric centre of the His-ring in PyMOL.[50]  
 
Ex vivo Brain Penetration Study 
To test the brain permeability, the compound 10a was subjected 
to an ex vivo determination of its AChE inhibitory activity as 
previously described.[76,77]  Briefly, the compound was 
administered intraperitoneally (ip) to young adult Wistar rats (2 
months of age) at either 10 or 50 μmol.kg-1. Experiments were 
performed in accordance with the Italian and European 
Community law for the use of experimental animals and were 
approved by a local bioethical committee. Animals were killed by 
decapitation at 2h after injection, brain was immediately 
dissected and cortices from both hemispheres were collected. 
Tissues were homogenized in ice-cold 50 mᴍ Tris-HCl buffer at 
pH=7.4 and added with Triton X-100 to a final 0.5% 
concentration (all chemicals were from Sigma-Aldrich). 
Homogenates were used to assay the AChE activity according 
to the standard colorimetric method[41] and to measure the total 
protein content for normalization.[78] AChE inhibition was not 
observed in the conditions used here. 
 
In vitro Blood–Brain Barrier Permeation Assay (PAMPA-
BBB). Prediction of the brain penetration was evaluated using a 
parallel artificial membrane permeation assay (PAMPA-BBB), in 
a similar manner as previously described.[62,16,63] Pipetting was 
performed with a semi-automatic pipettor (CyBi®-SELMA) and 
UV reading with a microplate spectrophotometer (Multiskan 
Spectrum, Thermo Electron Co.). Commercial drugs, phosphate 
buffered saline solution at pH=7.4 (PBS), and dodecane were 
purchased from Sigma, Aldrich, Acros, and Fluka. Millex filter 
units (PVDF membrane, diameter=25 mm, pore size=0.45 μm) 
were acquired from Millipore. The porcine brain lipid (PBL) was 
obtained from Avanti Polar Lipids. The donor microplate was a 
96-well filter plate (PVDF membrane, pore size 0.45 μm) and the 
acceptor microplate was an indented 96-well plate, both from 
Millipore. The acceptor 96-well microplate was filled with 200 μL 
of PBS:ethanol (70:30, v/v) and the filter surface of the donor 
microplate was impregnated with 4 μL of porcine brain lipid 
(PBL) in dodecane (20 mg.mL-1). Compounds were dissolved in 
PBS:ethanol (70:30, v/v) at 100 μg.mL-1, filtered through a Millex 
filter, and then added to the donor wells (200 μL). The donor 
filter plate was carefully put on the acceptor plate to form a 
sandwich, which was left undisturbed for 120 min at 25 ºC. After 
incubation, the donor plate is carefully removed and the 
concentration of compounds in the acceptor wells was 
determined by UV-Vis spectroscopy. Every sample is analyzed 
at five wavelengths, in four wells and at least in three 
independent runs, and the results are given as the mean ± 
standard deviation. In each experiment, 11 quality control 
standards of known BBB permeability were included to validate 
the analysis set. 
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GLOSSARY 
 
AAPH, 2,2’-azobis(amidinopropane) dihydrochloride, A, -
amyloid; ACh, acetylcholine; AChE, acetylcholinesterase; 
AChEIs, acetylcholinesterase inhibitors; AD, Alzheimer’s 
disease; ADMET, Absorption/Distribution/Metabolism/ 
Excretion/Toxicity; ATCh, acetylthiocholine iodide; BBB, blood-
brain barrier; BuChE, butyrylcholinesterase; BTCh, 
butyrylthiocholine iodide; CAS, catalytic anionic site; ChEs, 
cholinesterases; DMSO, dimethyl sulfoxide; DTNB, 5,5’-
dithiobis-2-nitrobenzoic acid; EDTA, 2,2',2'',2'''-(Ethane-1,2-
diyldinitrilo)tetraacetic acid; EeAChE, Electricus Electrophorus 
acetylcholinesterase; eqBuChE, equine butyrylcholinesterase; 
EMEM, Eagle’s minimum essential medium; FA, ferulic acid; 
FBS, fetal bovine serum; FDA, Food and Drug Administration; 
FL, fluorescein; hAChE, human recombinant 
acetylcholinesterase; hAChEIs, human recombinant 
acetylcholinesterase inhibitors; hBuChE, human serum 
butyrylcholinesterase; hChEs, human cholinesterases; HepG2, 
human liver hepatocellular carcinoma cell line; HFIP, 1,1,1,3,3,3-
Hexafluoro-2-propanol; MeOH, methanol; MDTLs, multi-target 
directed ligands; 7-MEOTA, 9-amino7-methoxy-1,2,3,4-
tetrahydroacridine; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide; NFT, neurofibrillary tangles; O/R, 
oligomycin A/rotenone; ORAC-FL, oxygen radical absorbance 
capacity-fluorescein; PAMPA, parallel artificial membrane 
permeability assay); PAS, peripheral anionic site; PBL, porcine 
brain lipid; PC12, rat pheochromocytoma cell line; ROS, reactive 
oxygen species; SH-SY5Y, human dopaminergic neuroblastoma 
cell line; TFAHs, tacrine-ferulic acid hybrids; ThT, thioflavin T, U-
4CR, Ugi four-component reaction.  
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